IL44127A - Imidazo(4,5-b)pyridines their preparation and pharmaceutical compositions containing them - Google Patents

Imidazo(4,5-b)pyridines their preparation and pharmaceutical compositions containing them

Info

Publication number
IL44127A
IL44127A IL44127A IL4412774A IL44127A IL 44127 A IL44127 A IL 44127A IL 44127 A IL44127 A IL 44127A IL 4412774 A IL4412774 A IL 4412774A IL 44127 A IL44127 A IL 44127A
Authority
IL
Israel
Prior art keywords
group
imidazo
phenyl
pyridine
general formula
Prior art date
Application number
IL44127A
Other versions
IL44127A0 (en
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2305339A external-priority patent/DE2305339C3/en
Priority claimed from DE2361757A external-priority patent/DE2361757A1/en
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of IL44127A0 publication Critical patent/IL44127A0/en
Publication of IL44127A publication Critical patent/IL44127A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/194Radicals derived from thio- or thiono carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/06Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Description

DR. KARL THOMAE GMBH C: 42100 The present invention relates to new imidazo [4,5-b] pyridines having interesting physiological properties-. ^ According to one feature of the present invention the and isomers thereof of general formula [wherein R^, and R^, which may be the same or different, each represents a hydrogen or halogen atom; a hydroxy, alkyl, allyloxy, benzyloxy, alkylthio, alkylsulfinyl or alkylsulfonyl group; an amino group optionally substituted bv one or two alkyl groups, a morpholino or a piperazino group « optionally substituted in : the 4-position by a phenyl group or an alkyl group containing from 1 to 3 carbon atoms, or an alkoxy group containing from 1 to 4 carbon atoms, optionally substituted by a halogen atom or by a.hydroxy,- alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino , piper-idino, morpholino, thiomorpholino, thiomorpholino-S-oxide , thio-morpholino-S,S-dioxide, 4-methylpiperazino , 4-phenylpiperazi "4-dimethoxyphenylpiperazino, 4-phenylethylpiperazino , " phenyl-ethylamino,. J K-methyl-phenylethylamino or N-methyl-dimethoxypheny ethylamino group; or two 44127/2 !. ( of the groups to together represent a methylene- dioxy group and the remaining R∑ , R2 or R3 group is as hereinbefore defined; each of the above mentioned alkyl groups containing from 1 to A carbon atoms; with the proviso that, if any two of the groups R , R2 and R„ represent hydrogen atoms, then the other group is other than" a hydrogen or a halogen atom, or a methyl or amino group.
• R" represents a hydrogen atom; an alkyl group optionally substituted by a hydroxy, dialkylamino , phenyl, dimethoxyphenylj piperidino, morpholino, 4- methylpiperazino or 4-phenylpiperazino group, each of the above mentioned alkyl groups containing from 1 to 4 carbon atoms, or a phenyl group optionally substituted by one or more halogen atoms or methoxy groups with the proviso that where R^ represents a hydrogen atom at least one of the groups ^ to R^ is other than hydrogen; and R,. represents a hydrogen atom, a halogen atom or a lower alkyl group] and the corresponding imidazo[ 4, 5-b] pyridine-N-oxides and isomers thereof and acid addition salts thereof.
In general the compounds of general formula I and isomers thereof of general formula la possess valuable physiological properties, in particular an activity on the blood pressure and heart force, a positive isotropic effect, an antiulcus activity, a platelet aggregation Preferred compounds according to the invention by virtue of their particularly favourable physiological properties are those(wherein R^, and R^. represent hydrogen atoms and and R^, which may be the same or different, each represents a halogen atom or a methyl, methoxy, ethoxy, alkylthio, alkylsulfinyl , dialkylamino-alkoxy, morpholinoalkoxy , thiomorpholinoalkoxy , 4-methylpiperazinoalkoxy , 4-phenylpiperazinoalkoxy or alkylsulfinylalkoxy group (wherein each alkyl group contains from 1 to 3 carbon atoms and each alkoxy group contains 2 or 3 carbon atoms )and physiologically compatible acid addition salts thereof. Particularly preferred are the following compounds :- 2- ( 2 , 4-Dimethoxy-phenyl) -1H- imidazo[ 4 , 5-b]pyridine and physiologically compatible acid addition salts thereof, 2- ( 2-Methoxy-4-methylmercapto-pheny1) -1H-imidazo-[4,5-b] pyridine and physiologically compatible acid addition salts thereof ^ 2- ( 2-Methoxy-4-methylsulfinyl-phenyl) 1H- imidazo [4,5-b] pyridine and physiologically compatible acid addition salts thereof, 2- ( 2-Methoxy-4-methyl-phenyl) -1H- imidazo[ 4, 5-b] pyridine and physiologically compatible acid addition salts thereof, 2- (2-Methoxy-5-methylmercapto-phenyl)-lH-imidazo [4,5-b] pyridine and physiologically compatible acid addition salts thereof, and 2- ( 2- Ethoxy-4-methy1-phenyl ) - 1H- imidazo[ 4 , 5-b] pyridine and physiologically compatible acid addition salts thereof.
The new compounds of general formula I and isomers thereof of general formula la as hereinbefore defined may be prepared by either of the following processes, which processes constitute further features of the invention: -a) Reaction of a compound of formula [wherein R<- is as hereinbefore defined arid Y represents a group of formula R. NH- (wherein R, is as hereinbefore defined)] with a compound of formula (wherein R^ to R^ are as hereinbefore defined and X represents a carboxyl, thiocarboxyl or dithiocarboxyl group) or a functional derivative thereof, for example an acid halide, anhydride, ester or orthoester; and b) Reaction of a compound of formula (wherein R,. is as hereinbefore defined and Y repr a halogen atom) with a compound of formula [wherein R^ to R^ are as hereinbefore defined and X represents an appropriate - R^ containing group (wherein R. is as hereinbefore defined) which is derived from a 4 carboxyl, thicarboxyl or dithiocarboxyl group, for example a nitrile, amide, amido ester, imido thioester, imido halide or amidine group].
In each case the reaction is preferably carried out in the presence of a solvent, suitable solvents including for example benzene, pyridine, glycol, toluene, acetone, diethylene glycol and triethylamine . However the reaction may also be performed in the absence of a solvent The reaction temperature used is determined by the reactivity of the group X in the compound of formula III used but generally the reaction is effected at temperatures" from -20 to 250 °C. If desired the reaction may be effected in the presence of an acid binding agent, such as pyridine or triethylamine , or in the presence of a catalytic quantity of an acid, such as p_-toluenesulfonic acid, or in the presence of a dehydrating agent, such as phosphorus oxychloride or thionyl chloride .
If for example a compound of formula III wherein X represents a carboxyl or amide group is used the reaction if conveniently carried out in the presence of phosphorus oxychloride or thionyl chloride, if desired in the presence of a tertiary organic base such as pyridine or triethylamine, preferably at temperatures from -20 °C up to the boiling point of the solvent used, e.g. at 120 °C.
If for example a compound of formula III wherein X represents a nitrile group is used, the reaction is conveniently performed in the presence of a catalytic quantity of an acid, such as p-toluenesulfonic acid, preferably at temperatures from 120 to 180 °C, e.g. at 160 °C, optionally in the presence of a solvent.
If for example a compound of formula III wherein X represents a thioamide group is used, the reaction is conveniently effected in the presence of a solvent, such as glycol, and preferably at temperatures from 100 to 150°C, e.g at 130°C.
If a compound of formula II wherein Y represents a halogen atom, e.g. a chlorine atom is used, the reaction is preferably carried out via the corresponding amidine, which is cyclized at elevated temperatures, e.g. at temperatures from 100 to 200 °C, optionally without previous isolation.
The compounds of general formula I and isomers thereof of general formula la containing a reactive halogen atom obtained according to the processes of the present invention rosy* if desired, be subsequently converted into the corresponding amino compounds with amines , and/or compounds of general formula I and isomers thereof of general formula la containing reactive hydrogen atoms, may if desired be subsequently alkylated by means of an alkylating agent in the presence of a base .
In addition a compound of formula I or an isomer thereof of formula la may if desired be converted into the corresponding N-oxide, S-oxide or S,S-oxide compound by means of an oxidizing agent. Finally a compound of formula I or an isomer thereof of. formula la may if desired be converted into an acid addition salt thereof, preferably into a physiologically compatible acid addition salt. Suitable acids include for example hydrochloric acid, hydrobromic acid, sulfuric acid, lactic acid, citric acid, tartaric acid, maleic acid and fumaric acid.
The starting compounds used for the processes according to the invention are known from the literature, or they may be prepared according to known processes (see Examples).
As already mentioned above, the new compounds of general formula I and isomers thereof of general formula la in general show valuable pharmacological properties, those which have been tested showing especially an activity on the blood-pressure, a positive inotropic activity, an antiulcus activity, a platlet aggregation inhibiting effect and a prolonging activity on the bleeding time.
The following compounds have been tested with respect to certain of their biological activities: A ■= 2^(2,4-Dimethoxy-phenyl)-lH-imidazo[4,5-b]pyridine hydrochloride, B = 2-[2-(2-Methylsulfinyl-ethoxy)-A-methoxy-phenyl]-lH- imidazo-[4,5-b]pyridine hydrochloride, , C = 2-(2-Methoxy-4-methylmercapto-phenyl)-lH-imidazo [4, 5-b]pyridine hydrochloride D = 2-(2-Methoxy-4-methylsulfinyl-phenyl)-lH-irnidazo [4,5-b]pyridine hydrochloride, , E = 2-(2-Methoxy-5-methylmercapto-phenyl)-lH-imidazo [4,5-b]pyridine hyrochloride F = 2-(2-Methoxy-4-methyl-phenyl)-lH-imidazo[4,5-b] pyridine hydrochloride G = 2-(2-Ethoxy-4-methoxy-phenyl)-lH-imidazo[4,5-b] pyridine hydrochloride, H = 2-(2-Ethoxy-4-methyl-phenyl)-lH-imidazo{4,5-b] pyridine hydrochloride, I = 2-(2-Methoxy-4-chloro-phenyl)-lH-imidazo[4,5-b] pyridine hydrochloride and J = 2-[ 2-(2-Methylsulfinyl-ethoxy)-4-methyltnercapto- phenyl]-lH-imidazo[4,5-b]pyridine hydrochloride The following known compounds were tested for comparison: K = 2-Phenyl-IH-imidazo [4 , 5-blpyridine hydrochloride, L = 2-(4- eth lphenyl)-IH-imidazo [4, 5-b] yridine, • M = 2-(4-Chlorophenyl)-IH-imidazo [4 , 5-b]pyridine hydrochloride. 1. Positive inotropic activity in the isolated auricle of the guinea-pig: . ■ Isolated auricles of guinea-pigs were put into an organ bath of 100 ml. The bath has been filled with a tyrode solution at a temperature of 30 °C. The tyrode solution was infused with carbogen (95% of C>2 and 5% of CO . The spontaneous contractions of the auricles were registered isometrically with a Statham-Force-transducer on a Grass- polygraph. The auricles were charged with 1 g. After sufficient equilibrating time, the substances in question were added to the organ bath. The concentration of the substance in the bath was 1 x 10 g/ml in each case. 5 auricles were used for each solution.
The following Table gives the results: Table I Substance Increase of the contraction- amplitude in % A 57.0 B 17.5 C 10.3 E 40.9 F 50.2 G 33.9 H 42.9 I 21.4 2. Circulation experiments on the narcotized cat; Cat were narcotized with 30 mg/kg of pentobarbital-sodium i.v. A plastic catheter was introduced into the arteria femoralis and into the left ventricle of the heart a steel catheter was introduced from the arteria carotis. With Statham-pressure-transducers of the type P23 AA and P23 Dc, the arterial blood-pressure and the pressure in the left ventricle was registered continuously.
From the ventricle-pressure-curve, the contractility parameters dp/dt and ν Γ, were continuously determined max CE by means of an analogous computer. The heart frequency was ascertained from the ventricle-pressure-curve using a tachograph. In addition, the EKG was registered in the II derivation.
All registrations were effected on a Brush-direct-writer. The substances were injected over a vena cannula into the vena femoralis. At least three cats were used for the test on each substance.
The following Table gives the results: Substehee Dose Blood-pressure alteration in otm Alteration of th i.v. traction force i ( None of the compounds showed any toxic side effects using the doses applied.
According to yet a further feature of the present invention there are provided pharmaceutical compositions comprising as active ingredient at least one compound of formula I or isomer thereof of formula la or physologi-cally compatible acid addition salt thereof in association with a pharmaceutical carrier or excipient.
The compositions may for example be presented in a form suitable for oral, rectal or parenteral administration Thus for example compositions for oral administration may be solid or liquid and may take the form of tablets, coated tablets or drops, such compositions comprising carriers or excipients conventionally used in the pharmaceutical art.
For parenteral administration the carrier may be a parenterally acceptable liquid, such as sterile water or a parenterally acceptable oil, e.g. arachis oil, contained in ampoules. For rectal administration compositions may take the form of suppositories, the carrier comprising a suppository base.
Advantageously the compositions may be formulated as dosage units . Each dosage unit preferably contains from 35 to 200 mg, preferably from 50 to 100 mg, of active ingredient.
The following Examples serve to illustrate the preparation of compounds according to the invention of pharmaceutical compositions containing the same.
Example 1 2- (2 ,4-Dimethoxypheny1)-1H-imidazo [ ,5-b]pyridine hydrochloride 54.5 g of 2 ,3-diaminopyridine and 91.1 g of 2,4- dimethoxybenzoic acid were finely pulverized and added in small amounts to 1500 ml of phosphorus oxychloride whilst stirring. Afterwards, the mixture was refluxed for 2 hours, and the phosphorus oxychloride was distilled off in vacuo. The residue was triturated with 2000 ml of 2N hydrochloric acid and the solid product obtained was suction filtered and recrystallized from water.
Yield: 121 g (85% of theory), m.p.: 238°C Example 2 2- (2 ,4-Dimethoxyphenyl)-lH-imidazo [4 ,5-b]pyridine hydrochloride 360 mg of 2 ,4-dimethoxybenzoic acid were dissolved in 2 ml of pyridine and a solution of 220 mg of 2 ,3-diaminopyridine in 2 ml of pyridine was added, whereupon the corresponding salt precipitated out. Whilst stirring and ice-cooling, 0.38 ml of phosphorus oxychloride were added dropwise and the mixture was stirred for a further hour at 0°C and 1 hour at room temperature. Subsequently the excess of pyridine was removed in vacuo and the residue was dissolved by adding dilute hydrochloric acid. The mixture was neutralized with sodium hydroxide solution and extracted with ethyl acetate. The ethyl acetate layer was evaporated, the residue was treated with a small quantity of 2N hydrochloric acid, and the precipitate was suction filtered and recry-τ· stallized from water.
M.p.: 238 to 239°C.
Example 3 2- (2 ,4-Dimethoxy-phenyl)-lH-imidazo[ ,5-b]pyridine hydrochloride Prepared analogously to Example 2 from 2,3-diaminopyridine , 2 ,4-dimethoxybenzoic acid and thionyl chloride.
M.p.: 238 to 239°C.
Example 4 2- ( 2 ,4-Dimethoxy-pheny1)- 1H-imidazo [ ,5-b]pyridine hydrochloride 900 mg of 2 ,4-dimethoxy-benzoic acid were converted into the acid chloride by heating in a mixture of 3 ml of benzene and 2 ml of thionyl chloride. Subsequently, the mixture was evaporated in vacuo and the residue obtained was taken up in 5 ml of benzene. This solution was dropped into a solution of 550 mg of 2 ,3-diamino-pyridine in 5 ml of pyridine whilst stirring. Afterwards, the mixture was heated for a short time at 60°C, then cooled to room temperature, and 0.9 ml of phosphorus oxychloride were added dropwise. After the mixture had been stirred for a further 3 hours at room temperature , 2N hydrochloric acid was added. The mixture was then neutrallized and extracted with ethyl acetate. The ethyl acetate layers were evaporated and a small quantity of 2N hydrochloric acid was added to the residue. The crystals which precipitated were suction filtered and recrystallized from water.
M.p.: 237 to 238°C.
Example 5 2- (2 ,4-Dimethoxy-phenyl)-lH-imidazo[4 ,5-b]pyridine hydrochloride a) 2-Amino-3-(2 ,4-dimethoxybenzoyl-amino) -pyridine hydrochloride 530 mg of 2 ,4-dimethoxybenzoic acid were converted into the acid chloride analogously to Example 4 and this acid chloride was dissolved in 1 ml of benzene. The solution obtained was added dropwise to a mixture of 440 mg of 2 ,3-diamino-pyridine , 3 ml of pyridine and 2 ml of triethylamine. After the whole mixture had been stirred for a further 2 hours at room temperature, water was added, the mixture was neutralized with concentrated hydrochloric acid and extracted with ethyl acetate. The ethyl acetate was removed, the residue was treated with dilute hydrochloric acid, the precipitated crystals were suction filtered and recrystallized from ethanol.
M.p.: 172 to 174°C. b) 2 >4-Dimethoxy-phenyl)-lH-imidazo[A t5-b]pyridine hydrochloride 155 mg of 2-amino-3-(2 ,4-dimethoxybenzoyl-amino)-pyridine hydrochloride were dissolved in 2 ml of pyridine. 0.2 ml of phosphorus oxychloride were dropped in whilst stirring at room temperature. After 2 hours the mixture was poured into water and worked up analogously to Example 4.
M.p.: 237 to 238°C.
Example 6 2- (2 >4-Dimethoxy-phenyl)-lH-imidazo[4 ,5-b]pyridine hydrochloride 155 mg of 2-amino-3-(2 ,4-dimethoxybenzoyl-amino)-pyridine hydrochloride were heated for 5 minutes at 200 -210°C. The mixture was treated with a small quantity of 2N hydrochloric acid, and the precipitate was filtered and recrystallized from water.
M.p.: 237 to 238°C.
\ V Example 7 2- ( 2 ,4-Dimethoxy-pheny1) - lH-imidazo [ ,5-b]pyridine hydrochloride 155 mg of 2-amino-3-(2 ,4-dimethoxybenzoyl-amino)- pyridine hydrochloride were refluxed for 30 minutes in 2 ml of glycol. The mixture was then diluted with water, neutralized, extracted with ethyl acetate and processed analogously to Example 4.
M.p.: 238 to 239°C.
Example 8 2- (2 ,4-Dimethoxy-phenyl)-lH-imidazo[4 ,5-b]pyridine hydrochloride 5.45 g of 2 ,3-diaminopyridine were added in small amounts to 150 ml of phosphorus oxychloride whilst stirring and 9.81 g of methyl 2 ,4-dimethoxybenzoate were also added dropwise. The mixture was then heated at 120°C. After two hours the excess of phosphorus oxychloride was evaporated in vacuo, the residue was digested with 2N hydrochloric acid and the solid product obtained was suction filtered and recrystallized from water.
M.p.: 238 to 239°C.
Example 9 2- ( 2 ,4-Dimethoxy-pheny1 ) - lH-imidazo [ , 5-b]pyridine hydrochloride 0.5 ml of morpholine were added whilst stirring to 470 mg of 2 ,4-dimethoxybenzoyl chloride in 6 ml of toluene. After 20 minutes the toluene was evaporated, the residue was treated with dilute hydrochloric acid and this mixture was extracted with ethyl acetate. After washing the ethyl acetate layer with sodium bicarbonate solution and evaporating off the solvent, crude 2 ,4-dimethoxybenzoyl-morpholine was obtained as oil. This oil was dissolved in 5 ml of pyridine, 250 mg of 2 ,3-diaminopyridine was added and finally 1 ml of phosphorus oxychloride was added dropwise whilst stirring and ice-cooling. After stirring for 5 hours at 0°C, ice-water was added, the mixture was made alkaline with concentrated ammonia, heated for a short time on the steam bath and extracted with ethyl acetate. The ethyl acetate was removed, and the residue obtained was treated with 2N hydrochloric acid, suction filtered and recrystallized from water.
M.p.: 238°C.
Example 10 2- (2 ,4-Dimethoxypheny1) - 1H-imidazo[4,5-b]pyridine hydrochloride 300 mg of 2 ,4-dimethoxybenzoyl-(4-chloro-anilide) and 110 mg of 2 ,3-diaminopyridine were mixed and added in small amounts to 3 ml of phosphorus oxychloride whilst stirring. Afterwards the mixture was refluxed for 8 hours. Then the phosphorus oxychloride was removed in vacuo, the residue was triturated with 2N hydrochloric acid and the solid product obtained was suction filtered and recrystallized from water.
M.p.: 237 to 238°C.
Example 11 2- (2 ,4-Dimethoxy-phenyl)-lH-imidazo[4 ,5-b]pyridine hydrochloride 600 mg of 2 ,4-dimethoxybenzoyl«(4-chloro-anilide) in a mixture of 5 ml of benzene and 2 ml of thionyl chloride were refluxed for 3 hours. After the mixture had been evaporated the crude 2 ,4-dimethyl-N-(4- chlorophenyl)-benzimidic acid chloride was obtained as an oil. This oil was dissolved in 9 ml of toluene and the solution was added to a solution of 200 mg of 2,3-di-aminopyridine in 10 ml of isopropanol. The mixture was heated for 10 minutes at 70°C. The 2 ,4-dimethoxy-benzoic acid-N- (4-chloropheny1) -N ' - (2-amino-3-pyridy1)-amidine hydrochloride which formed was not isolated but was dissolved in 20 ml of glycol after removing the isopropanol in vacuo. The glycol solution was refluxed for 10 minutes. Subsequently water was added, the mixture was made alkaline with concentrated ammonia, extracted with ethyl acetate and worked up as described in Example 4. M.p.: 237 to 238°C.
Exam le 12 2-(2 ,4-Dimethoxy-phenyl)-lH-imidazo[4,5-b]pyridine hydrochloride 100 mg of 2,3-diaminopyridine, 200 mg of 2,4-dimethoxybenzonitrile and 400 mg of p-toluenesulfonic acid monohydrate were mixed together and heated for 3¾ hours at 160°C. The product was triturated with dilute ammonia and ethyl acetate until the whole product had dissolved. The aqueous layer was extracted with ethyl acetate. After some time, when the combined ethyl acetate layers had been extracted with a small quantity of 2N hydrochloric acid, the product crystallized out from the aqueous phase.
M.p.: 237 to 238°C.
Example 13 2- ( 3 ,4 ,5-Trimethoxypheny1)-1H-imidazo [ ,5-b]pyridine 3.4 g of p-toluenesulfonic acid monohydrate and 15 ml of benzene were heated at 120°C until all the benzene had evaporated. Subsequently 1.1 g of 2 ,3-diaminopyridine and 2 g of 3 ,4 ,5-trimethoxybenzoyl nitrile were added and the mixture was heated for 2 hours at 150°C. After cooling, water was added, the mixture was extracted with ethyl acetate, the ethyl acetate layers were washed with dilute sodium hydroxide solution, evaporated and the residue was recrystallized from isopropanol/petroleum \ ether.
M.p.: 226°C.
Example 14 2- (3 t4.5-Trimethoxy-phenyl)-lH-imidazo[4,5-b]pyridine A mixture of 4.2 g of 3,4,5-trimethoxybenzoic acid and 2.2 g of 2 ,3-diaminopyridine was refluxed for 2 hours in 40 ml of phosphorus oxychloride. Subsequently the excess of phosphorus oxychloride was distilled off, water was added to the residue and the precipitated solid product was suction filtered. The product was dissolved in hot water, made alkaline with concentrated ammonia, and the precipitate was suction filtered and recrystallized from a small quantity of isopropanol.
M.p.: 225 to 226°C.
Example 15 2- (2 ,5-Dimethoxy-pheny1)- 1H-imidazo [4 , 5-b]pyridine a) 2 ,5-Dimethoxy-thiobenzoyl morpholide A mixture of 10 g of 2 , 5-dimethoxybenzaldehyde , 10 g of morpholine and 4 g of sulfur was heated at 130°C for 3½ hours and subsequently dissolved in 300 ml of hot ethanol. The product which precipitated out on cooling, was recrystallized from ethanol.
M.p.: 127°C. b) S-Methyl-2 ,5-dimethoxy-thiobenzoyl morpholide iodide 6 g of 2 ,5-dimethoxy-thiobenzoyl morpholide, 6.5 g of methyl iodide and 30 ml of acetone were refluxed for 8 hours. Subsequently the precipitated solid product was suction filtered and washed with ether. The product obtained was not purified further. c) 2- ( 2 ,5-Dimethoxy-pheny1) -1H-imidazo [ ,5-b]pyridine 2 g of S-methyl-2 ,5-dimethoxy-thiobenzoyl morpholide iodide and 1.1 g of 2 ,3-diaminopyridine were heated in 30 ml of glycol for 40 minutes at 130°C. Subsequently the mixture was poured on ice-water, suction filtered and recrystallized from ethanol/water.
M.p.: 235°C.
Example 16 2-(4-Hydroxy-phenyl)-lH-imidazo[4,5-b]pyridine a) 4-Hydroxy-thiobenzoyl morpholide Prepared analogously to Example 15a from 12.2 g of 4-hydroxy-benzaldehyde , 16 g of morpholine and 3.2 g of sulfur.
M.p .: 205°C b) S-Methyl-4-hydroxy-thiobenzyl morpholide iodide Prepared analogously to Example 15b from 14.4 g of 4-hydroxy-thiobenzyl morpholide and 2.1 g of methyl iodide in 100 ml of acetone.
M.p.: 181°C. c) 2-(4-Hydroxy-phenyl)-lH-imidazo[4,5-b]pyridine 1.84 g of S-methyl-4-hydroxy-thiobenzyl morpholide iodide were heated for 20 minutes at 130°C with 1.1 g of 2 ,3-diaminopyridine in 30 ml of glycol. The product precipitated whilst cooling and was dissolved in sodium hydroxide solution and reprecipitated with an acid.
Analysis: Calculated: 65.87% C 5.13% H 16.46% N Found: 65.90% C 5.16% H 16.47% N Example 17 2- [4-Methoxy-2-(3-chloropropoxy)-phenyl]-lH-imidazo [4,5-b]pyridine hydrochloride a) 4-Methoxy-2-(3-chloro-propoxy) -benzoyl morpholide 21.9 g of 2-hydroxy-4-methoxy-benzoyl morpholide were dissolved in 200 ml of dimethylformamide and 11.2 g of potassium tert.-butoxide were added. After the whole product had dissolved, 50 g of l-chloro-3-bromopropane were added and the mixture was heated for 2 hours at 130 °C. Subsequently the mixture was evaporated in vacuo, the residue was dissolved in ethyl acetate, and the solution was washed with sodium hydroxide solution and water and evaporated . b) 2-[4-Methoxy-2-(3-chloropropoxy)-phenyl]-lH-imidazo [4,5-b]pyridine hydrochloride 20 g of 4-methoxy-2-(3-chloro-propoxy)-benzoyl morpholide, 7 g of 2 ,3-diamino-pyridine and 170 ml of phosphorus oxychloride were refluxed for 2 hours. After evaporation of the phosphorus oxychloride, the residue was mixed with water, neutralized with sodium hydroxide solution and extracted with ethyl acetate. The hydrochloride was precipitated with ethereal hydrochloric acid.
M.p.: 198°C (decomp).
Example 18 2- [4-Methoxy-2-(2-chloroethoxy) -phenyl ]-lH-imidazo [ ,5-b]pyridine hydrochloride a) 4-Methoxy-2- (2-hydroxy-ethoxy) -benzoyl morpholide 23.7 g of 2-hydroxy- -methoxy-benzoyl morpholide, 33.6 g of potassium tert . -butoxide and 37.4 g of ethylene bromohydrin were heated in 100 ml of dimethylformamide for 6 hours at 120°C. After evaporation in vacuo, the residue was dissolved in chloroform and the solution was washed with sodium hydroxide solution and water and evaporated. b) 2- [4-Methoxy-2-(2-chloroethoxy) -phenyl ]-lH-imidazo [4 ,5-b]pyridine hydrochloride 2.8 g of 4-methoxy-2-( 2-hydroxy-ethoxy) -benzoyl morpholide, 1.1 g of 2 ,3-diaminopyridine and 20 ml of phosphorus oxychloride were refluxed for 2 hours. After evaporation water was added, the mixture was neutralized, extracted with ethyl acetate and the hydrochloride was precipitated with ethereal hydrochloric acid from the organic layer.
M.p.: 110°C (decomp.).
Example 19 2- [4-Methoxy-2-(3-chloropropoxy)-phenyl]-lH-imidazo [4,5-b]pyridine hydrochloride a) 4-Methoxy-2-(3-chloropropoxy)-benzoyl anilide 2.5 g of 2-hydroxy-4-methoxy-benzoyl anilide, 5 ml of l-chloro-3-bromopropane , 1.12 g of potassium tert.-butoxide and 20 ml of dimethylformamide were heated for 2 hours at 130°C. Subsequently the mixture was evaporated in vacuo , water was added and the mixture was suction filtered.
M.p. : 87 to 90°C. b) 2- [4-Methoxy-2-(3-chloropropoxy)-phenyl]-lH-imidazo [4 ,5-b]pyridine hydrochloride Prepared analogously to Example 17b from 4-methoxy- 2- (3-chloropropoxy) -benzoyl anilide and 2 ,3-diamino- pyridine .
M.p.: 198°C.
Example 20 2- [4-Methoxy-2- ( 3-morpholino-propoxy) -phenyl ]-lH-irnidazo [4 t5-b]-pyridine 0.5 g of 2- [4-methoxy-2-( 3-chloroproxy) -phenyl ]-1Η- imidazo[4,5-b]-pyridine hydrochloride were refluxed for 4% hours in 5 ml of morpholine. Water was then added, the precipitate was suction filtered and recrystallized from water.
M.p.: 108 to 110°C.
Example 21 2- [4-Methoxy-2-(2-(4-phenyl-l-piperazinyl)-ethoxy)-pheny1]-1H-imidazo [4 ,5-b]pyridine Prepared from 1.7 g of 2-[4-methoxy-2-(2-chloro-ethoxy)-phenyl]-lH-imidazo[4 ,5-b]pyridine and 3.2 g of 1-phenylpiperazine by boiling for 8 hours in ethanol.
M.p.: 164 to 165°C (from isopropanol) Example 22 2- [4-Methoxy-2- ( 3-dimethylamino-propoxy) -phenyl ]- 1H- imidazo [4 ,5-b]pyridine ..·. hydrochloride · 1.8 g of 2- [4-methoxy-2-(3-chloropropoxy)-phenyl]- lH-imidazo[4,5-b]-pyridine hydrochloride and 20 ml of saturated dimethylamine solution in ethanol were heated for 8 hours in a closed vessel at 100°C. Subsequently the mixture was evaporated in vacuo and recrystallized from isopropanol.
M.p.: 209 - 210°C Example 23 2- [4-Methoxy-2- ( 3-dimethylamino-propoxy) -phenyl ]- 1H-imidazo- [4 ,5-b]pyridine dihydrochloride 1.64 g of 4-methoxy-2-( 3-dimethylamino-propoxy) -thiobenzoyl morpholide were dissolved in a mixture of 17 ml of glacial acetic acid and 3 ml of acetic anhydride. 1 ml of dimethyl sulfate was added and the mixture was heated on the steam bath for 1 hour. Subsequently, the mixture was evaporated in vacuo. The crude S-methyl-4-methoxy-2- (3-dimethylamino-propoxy) -thiobenzoyl morpholide methyl sulfate obtained was dissolved in 13 ml of glycol 0.7 g of 2 ,3-diaminopyridine was added and the mixture was heated for 2 hours at 160°C. Subsequently, the mixture was poured into 50 ml of water, 5 ml of concentrated ammonia were added and the mixture was extracted with ethyl acetate. The ethyl acetate layers were evaporated, the residue was dissolved in ethanol, ethereal hydrochloric acid was added and it was again evaporated. The residue crystallized after trituration with toluene and a small quantity of ethanol. The product was suction filtered and recrystallized from isopropanol.
M.p.: of the dihydrochloride hydrate: 228 to 235°C (decomp.).
Exam le 24 2- ( 2 ,4-Dimethoxy-pheny1)-3-methy1-3H-imidazo [ ,5-b] pyridine ; 800 mg of 2 ,4-dimethoxybenzoyl methylamide were refluxed for 3 hours with 500 mg of 2-chloro-3-aminopyridine in 10 ml of phosphorus oxychloride. Subsequently, the mixture was poured into water, neutralized with concentrated ammonia and extracted with ethyl acetate.
After evaporation, the crude N-methyl-N'-(2-chloro-3-pyridyl) -2 ,4-dimethoxy-benzamidine obtained was dissolved in 10 ml of 10% glycolic sodium hydroxide solution and heated for 4 hours at 180 to 190°C. The mixture was poured into water and extracted with ethyl acetate. The compound obtained was purified by column chromatography (silica gel, eluent CHC13: MeOH = 19 : 1).
M.p. of the hydrochloride: 196 to 197°C Example 25 2- ( 2 ,4-Dimethoxy-phenyl) -3- (4-chloropheny1) - lH-imidazo [4,5-b] pyridine . 3 g of 2 ,4-dimethoxy-benzoyl (4-chloroanilide) and 1.3 g of 2-chloro-3-aminopyridine were refluxed for 2 hours in 16 ml of phosphorus oxychloride. Subsequently the mixture was poured into water, neutralized with concentrated ammonia and extracted with ethyl acetate. The ethyl acetate layer was extracted with 3N hydrochloric acid.
After neutralization of the aqueous layer, the mixture was again extracted with ethyl acetate. The solid product remaining after evaporation of the organic layer was recrystallized from methanol.
M.p.: 176 to 178°C.
Example 26 2- ( 2 , -Dimethoxy-pheny1) -1H-imidazo [4 ,5-b]pyridine hydrochloride 2.2 g of 2 ,3-diaminopyridine , 6.8 g of the imide chloride of 2 ,4-dimethoxy-benzoyl morpholide and 12 ml of triethylamine were heated for ¾ hour at 120 °C in 10 ml of diethyleneglycol dimethyl ether. After cooling, water was added, the reaction mixture was extracted with chloroform and the chloroform layer was extracted with 2N sodium hydroxide solution. The yellow hydrochloride which precipitated from the acidic solution was converted into the base with ammonia, and was purified by column chromatography. The hydrochloride was again precipitated from acetone with ethereal hydrochloric acid.
M.p. : 237 to 238°C. refluxed for 1 hour in 150 ml of acetone with 25 ml of methyl iodide and the precipitated yellow crystals were suction filtered after cooling.
Yield: 64.4 g (85% of theory) , m.p. : 162 to 164°C c) 2- (2-Methoxypheny1)-1H-imidazo [4 ,5-b]py idine . 19 g of 2-metho ^ M.p.: 233 to 234°C. 44127/3 V.' Example 29 . 2- (2-Methoxypheny1)-3-me hy1-3H-imldazo[ ,5-blpyridltie hydrochloride Prepared analogously to Example 28 from 2-methyl- -thip amino-3-amino-pyridine and 2-methoxy-Denzoyl .fchiomorpholide methiodide.
M.p.: 208 - 210°C Example 30 2- [2-(2-Methoxy-ethoxy)-pheny1]-1H-imldazo [4 ,5-b]pyridine hydrochloride Prepared analogously to Example 28 fron 2-(2-methoxy- -thio ethoxy)/«benzoyl -fckiemorpholide methiodide and 2 ,3-diamino-pyridine.
M.p.: 170 to 172°C Example 31 2-(4-Methoxyphenyl)-lH-imidazo[4t5-b]pyridlne- hydrochloride Prepared analogously to Example 28 form 4-methoxy- thio benzoyl -thiomorpholide methiodide (m.p.: 142 to 144°C) and 2 ,3-diamino-pyridine. -M.p.: 243 to 245°C. 44127-2 ' Example 32 2- (3-Methoxy -hydroxy-pheny1)-1H-imldazo [ ,5-b]pyridine hydrochloride Prepared analogously to Example 28 from 3-methoxy- - hio 4-hydro-¾p-benzoyl -bfeiemorpholide methiodide (m.p.: 178 to 180°C) and 2 ,3-diaminopyridine.
M.p.: 251 to 254eC.
Example 33 2- (2 t3-Dimethoxy-pheny1) -lH-imidazo [4.5-b]pyridine hydrochloride Prepared analogously to Example 28 from 2 ,3-dimethoxy-thio -benzoyl 'fchiomorpholide methiodide (m.p.: 138 to 140°C) and 2 ,3-diaminopyridine M.p.: 270 - 272°C Example 34 2*(2-Hydroxy-4-methoxy-phenyl)-lH-imidazo[4,5-b]pyridine hydrochloride Prepared analogously to Example 28 from 2-hydroxy- -thiQ . 4-methoxjrr|&enzoyl ibfeiemorpholide methiodide (m.p.: 180 to 181°C) and 2 ,3-diaminopyridine.
M.p.: 190 to 192°C (decomp.).
M.p. of the free base: 292 to 293°C Example 35 2- (2 ,4-Dimethoxy-pheny1)-1H-imidazo [4 ,5- ]pyridlne , hydrochloride Prepared analogously to Example 28 from 2,4- -thio dlmethoxybenzoyl fchiomorpholide methiodlde (m.p.: 138 to 140°C (decomp.)) and 2 ,3-diaminopyridine.
M.p.: 238°C (from methanol) Example 36 2- ( 2 ,4-Dimethoxy-phenyl)-6-methyl-lH-Imidazo [4 ,5-b] pyridine hydrochloride Prepared analogously to Example 35 from 2,3-diamino- -thio 5-methyl-pyridine and 2 ,4-dimethoxy-benzoyl ' ¾iemorph0lide methiodlde.
M.p.: 260 to 261°C.
Example 37 2- (2 ,4-Dimethoxy-pheny1)-7-methy1-1H-imidazo [4 ,5-b] pyridine hydrochloride Prepared analogously to Example 35 from 2,3-diamino- 4-methyl-pyridine and 2 t rombrpholide methiodide.
M.p. : 230 to 231°C.
Example 38 2- (21 -Dlmethoxy-pheny1)-5-methy1-1H-imidazo [4 ,5-b] pyridine hydrochloride Prepared analogously to Example 35 from 2 ,3-diamino- 6-methyl-pyridine and 2 methiodide.
M.p.: 245 to 246°C.
Example 39 2-(2 >4-Dimethoxy-phenyl)-6-chloro-lH-imidazo[4,5-b] pyridine hydrochloride Prepared analogously to Example 35 from 2,3-diamino- , , -thio 5-chloro-pyridine and 2 ,4-dimethoxy-benzoyl •fchiomorpholide methiodide .
M.p.: 253 to 255°C.
Example 40 2-(2-Ethoxy-4-methoxy-phenyl)-lH-imidazo[4,5-blpyridine hydrochloride Prepared analogously to Example 28 from 2-ethoxy-4-methox¾ binzoyl .fckiernorpholide methiodide (m.p.: 152 to 154°C) and 2 ,3-diamino-pyridine.
M.p.: 228 to 230°C.
Example 41 2- (2-Methoxy-4-ethoxy-phen 1)-1H-imidazo [4 ,5-b]pyrldine hydrochloride Prepared analogously to Example 28 from 2-methoxy-4-ethoxyk¾e%zoyl ^haromorpholide methiodide and 2 ,3-diaminopyridine.
M.p.: 224 to 225°C (from methanol) Example 42 2-(2 ,4-Diethoxy-phenyl)-lH-imidazo[4,5-b]pyridine hydrochloride Prepared analogously to Example 28 from 2 ,4-diethoxy-thio j benzoyl trtomorpholide methiodide and 2 ,3-diaminopyridine.
M.p,: 224 to 226°C Example 43 2-[2-(2-Hydroxy-ethoxy)-4-methoxy-phenyl]-lH-lmldazo[4t5-b]- pyridine hydrochloride Prepared analogously to Example 28 from 2-(2-hydroxy- "•thio ethoxy)-4-methoxy-benzoyl -fet»?emorpholide methiodide and 2 ,3-diaminqpyridine.
M.p.: 237 to 239°C.
Example 44 2- [2- (3-Hydroxy-propoxy)-4-methoxy-pheny1]-IH-imidazo [4 ,5-b] pyridine hydrochloride Prepared analogously to Example 28 from 2-(3-hydroxy-propoxy)-4-methoxy-'Denzoyl ttrtomorpholide methiodide and 2 ,3-diaminopyridine.
M.p.: 170°C (whilst sintering) Example 45 2- [2- (2-Methoxy-ethoxy) -4-methoxy-phen 1]-1H-imidazb [4 »5-b]-pyridine hydrochloride Prepared analogously to Example 28 from 2-(2- -thio methoxy-ethox )-4-methoxy-benzoyl thiomorpholide methiodide and 2 ,3-diaminopyridine.
M.p. : 191 to 193°C.
Example 46 2- [2-Methoxy-4- (2-methylmercapto-ethoxy) -pheny1 ]- 1H-imidazole ,5-b]pyridine hydrochloride a) 4-(2-Methylmercapto-ethoxy)-2-hydroxy-benzaldehyde 12 g of 2 ,4-dihydroxy-benzaldehyde and 9,6 g of potassium tert.- butoxide were dissolved in 50 ml of ethylene glycol monomethyl ether, 9.6 g of methylmercapto-ethyl chloride were added and the reaction mixture was stirred for 8 hours at 80°C (bath temperature). After removing the solvent, the residue was dissolved in dilute sodium hydroxide solution, the mixture was extracted twice with chloroform, the aqueous alkaline solution was separated, acidified and extracted with chloroform. The organic phase was dried and evaporated. The residue was purified by column chromatography (silica gel). The oil thus obtained was processed directly. b) 4-(2-Methylmercapto-ethoxy)-2-methoxy-benzaldehyde 9.7 g of 4-(2-methylmercapto-ethoxy)-2-hydroxy-benzaldehyde were dissolved in ethanol together with 6.7 g 44127-2 of potassium tert ,-butoxide 4.3 ml of dimethyl sulfate were added and the mixture was refluxed for 3 hours. A further 1 ml of dimethyl sulfate was then added and the mixture was heated for 1 hour more. After the ethanol had been distilled off the residue was dissolved in water/ chloroform and 2N sodium hydroxide solution was added.
The chloroform layer was separated, washed with water, dried and evaporated.
M.p.: 99 to 100°C (from cyclohexane) ' . -thio c) 4-(2-Methylmercapto-ethoxy) -2-methox -benzoy1 "Shiemorpholide Prepared analogously to Example 28a from 4-(2-methylmercapto-ethoxy)-2-methoxy-benzaldehyde.
M.p.: 131 to 132°C (from ethanol) d) 2- [2-Methoxy-4-(2-methylmercapto-ethoxy)-phenyl]-1H- imidazo [4,5-b]pyridine hydrochloride 5.4 g of 4- (2-methylmercapto-ethoxy)-2-methoxy- thio benzoyl -ifhtomorpholide were refluxed for 1½ hours together with 1.2 ml of methyl iodide in 50 ml of acetone.
After cooling, the solvent was removed and the syrupy methiodide obtained was heated with 3.6 g of 2 ,3-diamino-pyridine in 20 ml of glycol for 1½ hours at 120°C. The mixture was diluted with water and extracted with chloroform. Subsequently, 2N hydrochloric acid was added to the organic layer and the yellow precipitate was suction filtered.
M.p.: 197 to 199°C (from methanol) Example 47 2-[2-Methoxy-4-(2-ethylmercapto-ethoxy)-phenyl]-lH-imidazoT [4,5-b] pyridine hydrochloride Prepared analogously to Example 46 from 4-(2-ethylmercapto-ethoxy)-2-methoxy|^¾enzoyl ¾fti?omorpholide and 2 ,3-diaminopyridine. The purification of the final product was effected by chromatography over silica gel and ; the precipitation of the hydrochloride was effected b dissolving the base in acetone and adding an excess of ethereal hydrochloric acid.
M.p.: 195 to 196eC. 44127-2 Example 48 2- [2-Methoxy-4-(3-methylmercapto-propoxy)-phenyl]-1Η- Imidazo [4,5-b]pyridine hydrochloride Prepared analogously to Example 46 from 4- (3- -thio methylmercapto-propoxy)-2-methoxy'benzoyl -thiomorpholide and 2 t3-diaminopyridine .
M.p.: 189 to 191°C (decomp.).
Example 49 2- [2-Methoxy-4-(3-ethylmercapto-propoxy)-phenyl ]-lH-imidazo- [4,5-b]pyridlne hydrochloride Prepared analogously to Example 46 from 4-(3-ethyl-mercapto-propoxy)-2-methox>j|-Denzoyl -fe -emorpholide and 2,3 -diaminopyridine .
M.p.: 183 to 185°C (decomp).
Example 50 2-[2-(2-Methylmercapto-ethoxy)-4-methoxy-phenyl]-lH-imidazo [4,5-b] pyridine hydrochloride Prepared analogously to Example 46 from 2-(2- -thio methylmercapto-ethoxy)-4-methoxy-benzoyl ¾hi«morpholide and 2 ,3-diamino-pyridine.
M.p. : 204 to 206°C (decomp.). 44127-2 Example 51 2- [2-(2-Ethylmercapto-ethoxy)-4-methoxy-phenyl]-lH- imldazo[ ,5-b] pyridine hydrochloride Prepared analogously to Example 46 from 2-(2- -thio ethylmercapto-ethoxy)-4-methoxj-benzoyl tfciemorpholide and 2 ,3-diaminopyridine.
M.p.: 193 to 195°C.
Exam le 52 2- [2-(3-Methylmercapto-propoxy)-4-methoxy«phenyl]-lH-imidazo. [4 ,5-b]pyridine hydrochloride Prepared analogously to Example 46 from 2-(3-methylmercapto-propoxy)-4-methox¾8nzoyl thiemorpholide and 2 ,3-diaminopyridine.
M.p. : 191 to 193°C.
Example 53 2-C2-(3-Ethylmercapto-propoxy)-4-methoxy-phenyl]-lH-imidazo[4,5-b]pyridine hydrochloride Prepared analogously to Example 46 from 2-(3-ethyl- -thlo mercapto-propoxy)-4-methoxj-benzoyl tefrisemorpholide and 2,3-diaminopyridine .
M.p.: 187 to 189°C . 44127-2 Example 54 2-(2 ,3 t4-Trimethoxy-phenyl)-lH-imidazo[4,5-b]. pyridine hydrochloride Prepared analogously to Example 28 from 2,3,4-trimethox>-Denzoyl -bfeiomorpholide methiodide (m.p.: 147 to 150°C) and 2 ,3-diaminopyridine.
M.p.: 231 to 233°C (decomp.)..
Example 55 2- (2-Methoxy-3 ,4-methylenedioxy-pheny1)-lH-imidazo [4,5-b]pyridine hydrochloride Prepared analogously to Example 28 from 2-methoxy-3 ,4-methylenedioxy^¾e¾zoyl ih÷omorpholide methiodide (m.p.: 109 to 111°C) and 2 ,3-diaminopyridine.
M.p.: 266 to 268°C.
Example 56 2-(2 ,4-Dimethoxy-3-hydroxy-phenyl)-lH-imldazo[4,5-b] pyridine hydrochloride Prepared analogously to Example 28 from 2 ,4-dimethoxy -3-hydroxy/-benzoyl -fcfei-omorpholide methiodide and 2,3-diaminopyridine .
M.p.: 115 to 118°C. 44127-2 Example 57 2- ( 2-Methoxy-4-chloro-phenyl) -lH-imidazo [ ,5-b]pyridine hydrochloride Prepared analogously to Example 28 from 2-methoxy- -thio 4-chlor Example 58 2- (2-Methoxy-4-methy1-phenyl)-1H-imldazo[4 ,5-b]pyridine hydrochloride Prepared analogously to Example 28 from 2-methoxy- -thio 4-methyl'-benzoyl thiOmorpholide and 2 ,3-diaminopyridine. M.p.: 256°C (decomp.).
Example 59 2- (2-Ethoxy-4-methyl-pheny1)- 1H-imidazo [4 ,5-bIpyridine hydrochloride Prepared analogously to Example 28 from 2-ethoxy-4- -thio ' ■ methy] benzoyl tfcl¾morpholide methiodide (m.p.: 142 to 144°C) and 2 ,3-diaminopyridine.
M.p;: 224 to 225°C (decomp.). 44127-2 Example 60 2-(2-Methoxy-4-methylmercapto-phenyl)-lH-lmidazo[4>5-b] pyridine hydrochloride Prepared analogously to Example ¾¾> from 2-hydroxy- 4-methylmercapto-benzoyl morpholide (m.p.: 124 to 129°C) and 2 ,3-diamino-pyridine.
M.p.: 232 to 234°C.
Example 61 2- (2-Methoxy-5-methylmercapto-pheny1) -1Ή-imidazo [4 ,5-b] pyridine hydrochloride Prepared analogously to Example 25 from 2-methoxy- 5-methylmereap o-benzoyl morpholide (m.p.: 106 to 108°C) and 2 ,3-diamino-pyridine.
M.p. : 247 to 248°C.
Example 62 2-(2-Methoxy-4-ethylmercapto-phenyl)-lH-imidazoC4,5-b] pyridine, hydrochloride Prepared analogously to Example 25 from 2-methoxy-4-ethylmercapto-benzoyl morpholide and 2 ,3-diaminopyridine. M.p.: 215 to 217°C. 44127/3 Example 63 2-(2-Methylmercapto-phenyl)-lH-im^dazo[4,5-b]pyridine hydrochloride / Prepared analogously to Example 28 from 2-methy 1-mercapt(o}-¾e¾zoyl -fehiomorpholide methiodide and 2,3- diaminopyridine .
M.p.: 185 to 187°C. .
Example 64 m . 2- ( 2 ,4-BismethyIfercapto-pheny 1 )-lH-imidazo [ , 5-b] pyridine hydrochloride Prepared analogously to Example 28 from 2 ,4-bismethyl -thio mercaptoj-benzoyl -thfomorpholide methiodide and 2 t3-diaminopyridine .
M.p. : 249 to 250°C. ' Example 65 2-[2-(2-Methylmercapto-ethoxy)-4-methylmercapto-phenyl]-lH-imidazo [4,5-b]pyridine hydrochloride Prepared analogously to Example 28 from 2-(2-methylmercapto-ethoxy)-4-methylmercapl?o D:enzoyl fchiemorpholide methbdide and 2 ,3-diaminopyridine.
M.p.: 180 to 182°C. . 44127-2 x.
Example 66 2- [2-(2-Diethylamino-ethoxy)-4-methyl-phenyl]-lH-imidazo [4,5-b]. pyridine hydrochloride Prepared analogously to Example 28 from 2-(2- -thio diethylamino-ethoxy)-4-methyl/-benzoyl thi-omorpholide . methiodide hydrochloride and 2 ,3-diaminopyridine.
M.p.: 221 to 223°C.
Example 67 2-(2«Allyloxy-4-methoxy-phenyl)-lH-imidazo[4>5-b]pyridine hydrochloride 16.5 g of 2-allyloxy-4-methoxy-benzoyl morpholide and 7.1 g of 2 ,3-diaminopyridine were powdered and intimately mixed and 30 ml of phosphorus oxychloride were added dropwise whilst stirring. Subsequentl the reaction mixture was refluxed for 3 hours, the excess of phosphorus oxychloride was removed and the residue Was decomposed with ice-water. The solution, which had been made alkaline with ammonia, was extracted with chloroform. The. organic solution was extracted with 2N hydrochloric acid and the aqueous phase was made, alkaline with ammohia and extracted with chloroform. The chloroform solution was dried, treated with charcoal/tonsi1 , filtered and evaporated. The residue was dissolved in acetone and the light yellow colored hydrochloride was precipitated with ethereal hydrochloric acid.
M.p.: 189 to 191°C.
Example 68 2- (2 ,4,5-Trimethoxy-phenyl)-lH-imidazo[4,5-b]pyridine hydrochloride a) 2- (2 ,4,5-Trimethoxy-phenyl)-l ,3-dithiolanium-iodine 50 g of 1.2 ,4-trimethoxybenzene and 150 g of 2-methylmercapto-l ,3-dithiolanium-methyl sulfate were stirred in 600 ml of glacial acetic acid for 4 hours at 70°C bath temperature. Subsequently, the solvent was removed, the residue was dissolved in a mixture of chloroform and water and an excess of potassium iodide solution was added to the aqueous layer, whereby the product precipitated as orange-colored crystals. b) 2- (2 ,4 ,5-Trimethoxy-pheny1)-1H-imidazo [4 ,5-b] pyridine hydrochloride 3.8 g of 2-(2 ,4,5-trimethoxy-phenyl)-l ,3-dithiolanium -iodide and 2.2 g of 2 ,3-diaminopyridine were heated for 10 minutes in 40 ml of glycol at 200°C. After cooling the mixture was extracted with ether and then with chloroform. The chloroform layer was extracted with 2N hydrochloric acid and the precipitated yellow hydrochloride was suction filtered and recrystallized from glycol.
M.p.: 278 to 280°C Example 69 2-(2't4>6-Trimethoxy-phenyl)-lH-imidazo[ ,5-b]pyridine hydrochloride a) 2- (2 ,4 ,6-Trimethoxy-phenyl)-l ,3-dithiolanium-iodide 33.6g of phloroglucinol-trimethyl ether and 105 g of 2-methylmercapto-l ,3-dithiolanium-methyl sulfate were held at 75°C for 6 hours in 200 ml of glacial acetic acid and the crystals which precipitated after standing overnight were suction filtered, dissolved in water and the iodide thereof was precipitated with potassium iodide solution.
M.p.: 153 to 154°C. b) 2-(2 ,4,6-Trimethoxy-phenyl)-lH-imidazo[4,5-b] pyridine hydrochloride 4 g of 2-(2 ,4 ,6-trimethoxy-phenyl)-l ,3-dithiolanium- iodide, 2.2 g of 2 ,3-diaminopyridine and 5 g of lead acetate were heated for 10 minutes in 75 ml of glycol. Subsequently the precipitated lead salt was filtered off, the filtrate was diluted with water and the precipitated product was suction filtered. After dissolving in methanolic hydrochloric acid, the product was purified by passage through a silica gel column (eluent: chloroform: methanol = 9:1) M.p.: 241 to 244°C (from ethanol) Example 70 2- (2 ,4-Dihydroxy-pheny1) - 1H-imidazo [4 ,5-b]pyridine hydrochloride Prepared analogously to Example 69 from 3-hydroxy-4- [1 ' ,3 ' -dithiacyclopentylidene- (21 ) ]-eyelohexadiene- (2,5)-one-(l) and 2 ,3-diaminopyridine.
M.p.: 298 to 301°C.
Example 71 2-(4-Dimethylamino-phenyl)-lH-imidago[4 ,5-b]pyridine hydrochloride Prepared analogously to Example 69 from 2(4-dimethyl amino-phenyl) -1 ,3-dithiolanium-iodide and 2,3-diamino-pyridine in n-propanol.
M.p. : 337 to 339 °C.
Example 72 : 2-(2-Methoxy-4-dimethylamino-pheny1) -1H-imidago [4 ,5-b] pyridine hydrochloride a) 2- (2-Methoxy-4-dimethylamino-phenyl)-! ,3-dithiolanium^ iodide 22.6 g of 3-dimethylamino-anisole , 43.2 g of 2-methylmercapto-1 ,3-dithiolanium-methyl sulfate , 150 ml of glacial acetic acid and 22.5 ml of pyridine were refluxed for ½ hour. After cooling, the mixture was poured into an aqueous potassium iodide solution, the precipitated product was suction filtered and dried.
M.p.: 189 to 195°C (from dimeth lformamide) b) 2- ( 2-Methoxy-4-dimethylamino-pheny1) - 1H-imidazo [4 ,5-b]pyridine hydrochloride Prepared analogously to Example 42 from 2-(2-methoxy- 4Tdimethylamino-phenyl)-l ,3-dithiolanium-iodide and 2 ,3-diaminopyridine .
M.p.: 258 to 260°C (from methanol) Example 73 2-(2-Methylsulfinyl-phenyl)-lH-imidazo [4 ,5-b]pyridine hydrochloride 1.35 g of 2- (2-methylmercapto-phenyl)-lH-imidazo [4 ,5-b]pyridine were dissolved in 20 ml of glacial acetic acid and 0.64 g of 30% hydrogen peroxide dissolved in 5 ml of glacial acetic acid were added dropwise. After standing overnight, the mixture was diluted with water, neutralized with sodium bicarbonate and the precipitated product was suction filtered and dried. By addition^ of ethereal hydrochloric acid to a methanolic solution of the product the colorless hydrochloride was obtained.
M.p. : 205 to 210°C. 4 127 Example 74 2-(2-Methylsulfonyl-phenyl)-lH-imidazo[4,5-b]pyridine hydrochloride 450 mg of 2-(2-methylmercapto-phenyl)-lH-imidazo [4,5-b]pyridine hydrochloride and 370 mg of 30% hydrogen peroxide were heated for 3 hours at 70°C in 20 ml of glacial acetic acid. After evaporation and trituration with petroleum ether, the desired product crystallized. M.p.: 259 to 262°C (from isopropanol) Example 75 2^[2-(2-Methylsulfinyl-ethoxy)-phenyl]-lH-imidazo[4.5-b] pyridine hydrochloride a) 2-[2-(2-Methylmercapto-ethoxy)-phenyl]-lH-imidazo [4,5-b]pyridine hydrochloride Prepared analogously to Example 28 from 2-(2- -thio methylmercapto-ethoxy^-benzoyl «fc½i«morpholide methiodide and 2 ,3-diaminopyridine.
M.P.;: 138 to 140eC. b) 2-[2-(2-Methylsulfinyl-ethoxy)-phenyl]-lH-imidazo [4 ,5-b]pyridine hydrochloride 4.3 g of 2- [2-(2-methylmercapto-ethoxy)-phenyl]-lH- imidazo [4,5-b]pyridine hydrochloride and 1.5 g of 30% hydrogen peroxide were stirred for 2 hours at room temperature in 100 ml of glacial acetic acid. After standing overnight, the mixture was diluted with water, neutralized with bicarbonate and extracted with chloroform. The chloroform layer was evaporated, the residue was dissolved in acetone and the hydrochloride was precipitated with methanolic hydrochloric acid.
M.p. : 163 to 165°C.
Example 76 2-[2-(2-Methylsulfinyl-ethoxy)-4-methoxy-phenyl]-lH-imidazof4 ,5-b]pyridine hydrochloride Prepared analogously to Example 75b from 2-[2-(2-methylmercaptp-ethoxy)-4-methoxy-phenyl]-lH-imidazo[4 ,5-b] pyridine hydrochloride M.p.: 231 to 232°C. i Example 77 2- [2- (2-Ethylsulfinyl-ethoxy) -4-methoxy-phenyl]-lH-imidazo [4,5-b], pyridine Prepared analogously to Example 75b from 2-[2-(2- ethylmercapto-ethoxy) -4-methoxy-phenyl]-lH-imidazo [4 ,5-b] pyridine hydrochloride.
M.p.: 138 to 189°C.
Example 78 2- [2- (3-Methylsulfinyl-propoxy) -4-methoxy-pheny1]-1H-imidazoii' [4 ,5-b]pyridine Prepared analogously to Example 75b from 2-[2-[2- ( 3-methylmercapto-propoxy)-4-methoxy-pheny1 ]- 1H-imidazo [4,5-b]pyridine hydrochloride M.p. : 132 to 133°C Example 79 2- [2- (3-Ethylsulfinyl-propoxy) -4-methoxy-pheny1 ]-1H-imidazo [4 ,5-b]pyridine Prepared analogously to Example 75b from 2-[2-(3-ethylmercapto-propoxy)-4-methoxy-phenyl]-lH-imidazo[4 ,5-b] pyridine hydrochloride.
M.p.: 126 to 127°C.
Example 80 2- (2-Methoxy-4-methy1sulfiny1-pheriy1) -1H-imidazo [4 ,5-b] pyridine hydrochloride 6.6 g of 2- (2-methoxy-4-methylmercapto-phenyl)-lH- imidazo[4 ,5-b]-pyridine were dissolved in 100 ml of chloroform and a solution of 2.96 g of 3-chloro-perbenzoic acid in 600 ml of chloroform was dropped in at -15 to -20°C during 5 hours. Subsequently, the mixture was extracted with a dilute sodium carbonate solution and the chloroform layer was dried and evaporated. The residue was purified over a silica gel column (eluent: chloroform/methanol = 9:1). By addition of ethereal hydrochloric acid to a methanolic solution of the base the yellow hydrochloride was obtained.
M.p.: 154 to 155°C.
Example 81 2-(2-Methoxy-4-methylsulfonyl-phenyl)-lH-imidazo[4 ,5-b] pyridine hydrochloride Prepared analogously to Example 74 from 2-(2-methoxy -4-methylmercapto-phenyl)-lH-imidazo [4,5-b]pyridine hydrochloride .
M.p.: 240 to 242°C.
Example 82 2-(2-Methoxy-4-ethylsulfinyl-phenyl)-lH-imidazo[4,5-b] pyridine hydrochloride Prepared analogously to Example 80 from 2-(2-methoxy-4-ethylmercapto-pheny1) -1H-imidazo [4 ,5-bjpyridine M.p.: 121 to 123°C Example 83 2- [2- (2-Methylsulfinyl-ethoxy)-4-methylmercapto-pheny1]-1H-imidazo [4 , 5-b]pyridine Prepared analogously to Example 80 from 2-[2-methylmercapto-ethoxy)-4-methylmercapto-phenyl]-lH-imidazo [4 ,5-b]pyridine and an equimolar quantity of 3-chloro-perbenzoic acid.
M.p.: 191 to 192°C (from acetone) Example 84 2- [2- (2-Methylsulfinyl-ethoxy)-4-methylsulfinyl-phenyl]-lH^ imidazo [4 ,5-b]pyridine Prepared analogously to Example 80 from 2-[2-(2-methylsulfin l-ethoxy)-4-methylmercapto-phenyl]-lH-imidazo [4 ,5-b]pyridine and an equimolar quantity of 3-chloro-perbenzoic acid.
M.p. : 190 to 191°C.
Example 85 2-[2-(2-Methylsulfinyl-ethoxy)-4-methyl-phenyl]-lH-imidazo [4 ,5-b] pyridine hydrochloride Prepared analogously to Example 75b from 2- [2- (2-methylmercapto-ethoxy)-4-methyl-phenyl]-lH-imidazo[4 ,5-b] pyridine hydrochloride.
M.p.: 191 to 192°C (from acetone/ether).
Example 86 2- [2-(2-Methylsulfinyl-ethoxy)-4-chlorophenyl]-lH-imidazo [4,5-b] pyridine hydrochloride Prepared analogously to Example 75b from 2-[2-(2-methymercapto-ethoxy)-4-chloro-phenyl]-lH-imidazo[4 ,5-b] pyridine hydrochloride.
M.p.: 221 to 222°C (from acetone/ether) .
Example 87 2- [^2-Methoxy-4-(2-methylsulfinyl-ethoxy) -phenyl ]-lH-imidazo [4,5÷b]pyridine Prepared analogously to Example 75 b from 2- [2-methoxy-4- (2-methylmercapto-ethoxy) -phenyl]-1H-imidazo [4,5-b]pyridine hydrochloride.
M.p, : 204 to 205°C.
Example 88 2- C2-Methoxy-4-(2-ethylsulflnyl-ethoxy)-phenyl]-lH-imidazo [4,5-b] pyridine Prepared analogously to Example 75b from 2- [2-methoxy-4-(2-ethyl-mercapto-eth0xy) -phenyl ]-lH-imidazo [4 ,5-b]pyridine hydrochloride.
M.p.: 217 to 219°C Example 89 2- [2-Methoxy-4-(3-methylsulfinyl-propoxy) -phenyl ]-1Η-imidazo [4 ,5-b]pyridine Prepared analogously to Example 75b from 2- [2-me hoxy-4- (3-methylmercapto-propoxy) -phenyl ]-1Η-imidazo [4,5-b]pyridine hydrochloride.
M.p.: 179 to 180°C.
Example 90 2- [2-Methoxy-4-(3-ethylsulfinyl-propoxy) -phenyl ]-lH-imidazo [4,5-b] pyridine hydrochloride Prepared analogously to Example 75b from 2- [2-methoxy-4- ( 3-ethylmercapto-propoxy) -phenyl ]- 1H-imidazo [4,5-b]pyridine hydrochloride M.p.: 167 to 168°C.
Example 91 2-(2-Methoxy-5-methylsulfinyl-phenyl)-lH-imidazo [4,5-b] pyridine Prepared analogously to Example 80 from 2-(2-methoxy- 5-meth lmercapto-pheny1 ) -1H-imidazo [ ,5-b]pyridine hydrochloride .
M.p. : 211 to 212°C.
Example 92 2-(2-Methoxy-5-methylsulfonyl-phenyl)-lH-imidazo [4,5-b] pyridine Prepared analogously to Example 74 from 2-(2-methoxy-5-methylmercapto-phenyl)-lH-imidazo[4,5-b]pyridine hydrochloride M,p. : 240 to 241°C.
Example 93 2^(2 ,4-Dimethoxy-phenyl-lH-imidazo[4>5-b]pyridine-oxide-(4) 1 g of 2- (2 ,4-dimethoxy-phenyl)-lH-imidazo[4,5-b] pyridine and 1.35 g of 3-chloroperbenzoic acid were stirred for 15 hours at 60°C in 15 ml of glacial acetic acid. Subsequently, the mixture was recrystallized from 2N acetic acid by addition of charcoal. The further purification was effected by boiling with acetone.
M.p.: 266 to 267°C.
Example 94 2- (2 ,4-Dimethoxy-phenyl)-3-methyl-3H-imidazo[4t5-b] pyridine hydrochloride 3.6 g of methyl iodide were added dropwise to a solution of 3.5 g of 2-(2 ,4-dimethoxy-phenyl)-lH-imidazo [4 ,5-b]pyridine hydrochloride and 27 g of potassium tert.r butoxide in 40 ml of dimethylformamide. The mixture was stirred for 2 hours at room temperature and then evaporated. The residue was dissolved in chloroform/ water, the organic layer was separated, dried and evaporated. The product was purified by column chromatography and subsequently precipitated from the solution in acetone with ethereal hydrochloric acid.
M.p.: 196 to 197°C.
Example 95 2- ( 2-Hydroxy-pheny1) -3-methy1-3H-imidazo [ 4, 5-b]pyridine hydrochloride Prepared analogously to Example 94 from 2-(2-hydroxy-phenyl)-lH-imidazo[4, 5-b]pyridine and methyl iodide. M.p. : 215 to 216°C.
Example 96 2- (2-Hydroxy-4-methoxy-pheny1) -3- (3-hydroxypropy1) -3H-lmidazo[4,5-b]pyridine hydrochloride Prepared analogously to Example 94 from 2- (2-hydroxy- 4-methoxy-pheny1)- 1H-imidazo[ 4, 5-b]pyridine and 3-bromo-propanol.
M.p. : 154 to 155°C. -Example 97 2-(2 , 4-Dimethoxy-pheny1)-3-benzy1-3H-imidazo[4, 5-b]pyridine hydrochloride Prepared analogously to Example 94 from 2-(2,4-dimethoxy-phenyl) - IH-imidazo[ 4, 5-b]pyridine and benzyl bromide.
M.p. : 148 to 150°C.
Example 98 - (2 , 4>-Dimethoxy-phenyl) -3- (2-diethylaminoethyl) -3H-imidazo-[4,5-blpyridine dihydrochloride Prepared analogously to Example 94 from 2- (2,4-dimethoxy-phenyl)-lH-im-Ldazo[4,5-b]pyridine and 2-dlethylamino-eth l chloride at 80°C.
M.p.: 185°C.
Example 99 2- ( 2 , 4-Dimethoxy-pheny1) -3- (3-dimethylaminopropy1) -3H- Prepared analogously to Example 94 from 2-(2,4-dimethoxy-phenyl)-lH-imidazo[4, 5-b]pyridine and 3-dimethylaminopropy1 bromide at 70°C.
M.p.: 190 to 192°C (decomp.).
Example 100 2- ( 2-Methoxy- 4-benzyloxy-pheny1) - 1H- imidazo[ 4, 5-b]pyridine Prepared analogously to Example 10 from 2-methbxy-4-benzyloxy-benzoyl morpholide and 2 ,3-diamino-pyridine .
M.p. of the hydrochloride: 218 to 219°C (decomp.).
Example 101 2- ( 2 , 4-Dimethoxy-pheny1) -3-buty1-3H-imidazo[4, 5-b]pyridine .
Prepared analogously to Example 10 from 2 ,4-dimethoxy benzoyl morpholide and 3-amino^2-butylamino-pyridine.
M.p. of the hydrochloride: 218 to 219°C.
Example 102 2- ( 2-Methoxy- 4-hydroxy-pheny1) - lH-imidazo[ 4 , 5-b]pyridlne Prepared analogously to Example 10 from 2-methoxy-4-hydroxy-benzoyl morpholide and 2,3-diamino-pyridine.
M.p. of the hydrochloride: 230 to 2316C.
Example 103 2- ( 2-Ethoxy- 4-eth lmercapto-pheny1) - 1H- imidazo[ 4 , 5-b]-pyridine Prepared analogously to Example 10 from 2-ethoxy-4-ethylmercapto-benzoyl morpholide and 2 ,3-diamino-pyridine, M.p. of the hydrochloride: 198 to 199°C (decomp.).
Example 104 2 [ 4-Methoxy- 2- ( 3- ( 4-methy1- 1-piperaziny1) -propoxy) -phenyl] -lH-imidazo[4> 5-b]pyridine Prepared analogously to Example 21 from 2-[4-methoxy-2-(3-chloro-propoxy)-phenyl]-lH-imidazo[4,5-b] pyridine and 1-methylpiperazine.
M.p. of the trihydrochloride: 248°C (decomp.) Example 105 2-C4-Methoxy-2- ( 2-thiomorpho1ine-etho y) -pheny1 ] - lH-imidazo[4, 5-b]pyridlne Prepared analogously to Example 21 from 2-[4-methoxy- 2- ( 2-chloro-ethoxy) -phenyl] - 1H- imidazo[ 4 , 5-b] - -pyridine and thiomorpholine.
M.p.: 158 to 160°C.
Example 106 2- ( 2-Fluoro-4-methoxy-phenyl) - IH- imidazo[ , 5-b]pyridine Prepared analogously to Example 1 from 2-fluoro-4-methoxy-benzoic acid and 2 ,3-diamino-pyridine.
M.p. of the hydrochloride: 237 to 238°C (decomp.).
Example 107 2- ( 4-Fluoro- 2-methoxy-pheny1) - IH- imidazo[ 4, 5-b]pyrjdine Prepared analogously to Example 1 from 4-fluoror 2-methoxy-benzoic acid and 2 ,3-diamino-pyridine .
M.p. of the hydrochloride: 235 to 236°C (decomp.).
Example 108 2-(2, 4-Dimethyl-phenyl)-lH-imidazo[4,5-b]pyridine Prepared analogously to Example 1 from 2 ,4-dimethyl-benzoic acid and 2 ,3-diamino-pyridine.
M.p. of the hydrochloride: 185°C.
Example 109 2- ( 2-Hydroxy- -methoxy-pheny1) -3-pheny1-3H- imidazo-r4t5-b]pyridine 4.9 g of 2-hydroxy-4-methoxy-benzanilide and 2.6 g of 2-chloro-3-amino-pyridine were refluxed for 1½ hours in 50 ml of phosphorus oxychloride. After distilling off the excess of phosphorus oxychloride the residue was boiled for 45 minutes with 2N hydrochloric acid, neutralized with ammonia and the precipitated product was recrystallized from isopropanol.
M.p.: 201°C.
Example 110 2- ( 2-Hydroxy- 4-methoxy-pheny1) -3- ( 2-methoxy-pheny1) -3H-imidazo[4>5-'b]pyridine Prepared analogously to Example 109 from N-(2-methoxy-phenyl)-2-hydroxy-4-methoxy-benzamide and 2-chloro- 3-amino-pyridine.
M.p.: 197°C.
Example 111 2- ( 2-Hydroxy- 4-methoxy-pheny1) -3- ( 4-methoxy-pheny1) -3H-imidazo[4, 5-b]pyridine Prepared analogously to Example 109 from N-(4-methoxy-phenyl)-2-hydroxy-4-methoxy-benzamide and 2-chloro-3r-amino-pyridine.
M.p.: 175°C.
Example 112 2- ( 2-Hydroxyr 4-methoxy-pheny1) -3- ( 2-phenylethy1) -3H-lmidazo[4, 5-b]pyridine .
Prepared analogously to Example 109 from N-(2-phenylethyl)-2-hydroxy-4-methoxy-benzamide and 2-chloro-3-amino-pyridine.
M.p.: 155°C.
Example 113 2f ( -Amino-phenyl) - 1H- imldazo[ , 5-b]pyridine Prepared analogously to Example 1 from 4-acetamino-benzoic acid and 2 ,3-diamino-pyridine and subsequently heating for 15 minutes with 2N hydrochloric acid.
M.p. of the dihydrochloride: )300°C.
Example 114 2- (2 >4-Dimethoxy-phenyl)-3-phenyl-3H-imidazo[4t5-b]pyrldine Prepared from N-phenyl-N'-(2-chloro-3-pyridyl)-2 ,4-dimethoxy-benzamidine by heating for 5 minutes with sodium hydride in dimethylformamide at 120°C.
M.p. : 138°C (from cyclohexane/isopropanol = 9/1).
Example 115 2r- 2 , 4-Dimethoxy-pheny1) -3- ( 2-methoxy-pheny1) -3H- imidazo-[4, 5-b]pyridine Prepared analogously to Example 114 from N-(2-methoxy-phenyl)-N' -(2-chloro-3-pyridyl) -2 ,4-dimethoxy-benzamidine.
M.p. : 156°C.
Example 116 2- ( 2 » fDimethoxy-pheny1) -3- ( -methoxy-pheny1) -3H-lmidazo[4> 5-b]pyrldine Prepared analogously to Example 114 from N- ( 4-methoxy-pheny1) -N ' - ( 2÷chloro-3-pyridy1) r2 , 4- dimethoxy-benzamidine .
M.p. : 163°C.
Example 117 . 2- ( 214-^Dlmethoxy-pheny1) -3- (3 , 4-dlmethoxy-pheny1) -3H-ImldazQ[4, 5-b]pyrldlne Prepared analogously to Example 114 from N-(3 , 4-dimethoxy-pheny1) - 1 - ( 2-chloro-3-pyridy1) -2 , 4-dimethoxy-benzamidine.
M.p.: 190°C.
Example 118 2- (3 , ^Dimethoxy-pheny1) -3- ( 4-methoxy-pheny1)-3H-imidazo- [ f 5- !)pyridlne Prepared fron N- ( 4-methoxy-pheny1)-Ν'-( 2->chloro>- 3-pyridyl)-2 ,4rdimethoxy-benzamidine analogously to Example 114 or by boiling in chlorobenzene.
M.p.: 181°C.
Example 119 2- ( 2 ,4-Dimethoxy-pheny1) -3- (3-morphollno- 1-propy1) -3H-imidazo 4 5"b ri ine Prepared analogously to Example 114 from N- ( 3-morpholino- 1-propyl) - ' ( 2-chloro-3-pyridy1) -2 , 4-dimethoxy-benzamidine .
M.p.: 207°C.
Example 120 2- (2 t6 Dlmethoxyphenyl)-lH-lmldazo[4, 5-b]pyridine hydrochloride 9.1 g of 2 ,6-dimethoxy-benzoic acid and 5.5 g of 2 ,3-diaminopyridine were refluxed for 3 hours in 100 ml of phosphorus oxychloride. Subsequently the excess of phosphorus oxychloride was distilled off and the residue was carefully decomposed with ice-water. The obtained solution was filtered, neutralized with potassium parbonate and made alkaline with concentrated ammonia. The suspension which formed was extrapted three times with chloroform. The chloroform layer was dried over magnesium sulfate, filtered and the solvent was removed. The remaining residue was dissolved i 50 ml of methanolic hydrochloric acid, subsequently 100 ml of isopropanol were added and the product was kept in the deep freezer overnight. The precipitate was suction filtered and washed with ether.
M.p. : 250 to 254°C - - Example 121 2-(2-Propoxy-4-methyl-phenyl)-lH-lmldazo[4>5-b]pyrldine hydrochloride Prepared analogously to Example 120 from 2-prppoxy-4-methyl-benzoyl morpholide.
M.p.: 221 to 223°C. (decomp.).
Example 122 2- (2-Butoxy-4-methyl-phenyl)-lH-imidazo[4, 5-b]pyridine hydrochloride Prepared analogously to Example 120 from 2-butoxy-4-methyl-benzoyl morpholide.
M.p.: 212 to 213°C (decomp.).
Example 123 2- ( 4-Methylmercapto-pheny1) - 1H- imidazo [ 4 , 5-b]pyridine hydrochloride Prepared analogously to Example 120 from 4-methyl-mercaptobenzoic acid.
M.p. : 230 to 232°C.
Example 124 2-C2- ( 2-Methylmercapto- ethoxy) - 5-methylmercapto-pheny1^| lH-imidazoC4, 5-b]pyridine hydrochloride 50 g of S-methyl-[2^(2-methy!mercapto-ethoxy)-5-methylmercaptoj-thiobenzoyl morpholide iodide (obtained by reaction of [ 2- (2-methylmercapto-ethoxy) -5-methylmercapto] -thiobenzoyl morpholide with methyl iodide in methanol) and 15 g of 2 ,3-diaminopyridine were heated for 3 hours at 130°C in 150 ml of glycol. After cooling, the mixture was diluted with water and 30 ml of concentrated ammonia were added. Subsequently, the mixture was extracted with chloroform, the organic layer was washed with water and 2N hydrochloric acid was added. The precipitate was suction filtered and recrystallized from methanol.
M.p. : 190 to 191°C.
Example 125 2- ( 2-Methoxy- -propyImercapto-phenyl) - IH- imidazo[ 4, 5-b]-pyridine hydrochloride Prepared analogously to Example 120 from 2-methoxy-4-propylmercapto-benzoyl morpholide.
M.p.: 203 to 204°C (decomp.).
Example 126 2- ( 2-Ethoxy- 4-propylmercapto-pheny1) - IH- imidazo [ 4 , 5-b] -pyridine hydrochloride Prepared analogously to Example 120 from 2-ethoxy-4-propylmercapto-benzoyl morpholide. ' -- _ M.p. : 182 to 183°C.
Example 127 2- ( 2-Methoxy- 4-butylmercapto-pheny1) - 1H-imidazo[4, 5-b]-pyridine hydrochloride Prepared analogously to Example 120 from 2-methoxy-4-butylmercapto-benzoyl morpholide.
M.p. : 203- to 204°C.
Example 128 2-(2-Ethoxy-4-butylmercapto-phenyl)-H-imidazo[4>5-b]-pyridine hydrochloride Prepared analogously to Example 120 from 2-ethoxy- 4-butylmercaptobenzoy1 morpho1ide.
M.p. : 207 to 208°C.
Example 129 2-( 4-Methylsulfinyl-phenyl)-lH-imidazo[4, 5-b]pyridine 5.9 g of 2- (4-methylmercapto-phenyl)-lH-imidazole4, 5-b]pyridine hydrochloride were dissolved in 100 ml of glacial acetic acid and 2.4 g of 30% hydrogen peroxide were added at 10°C. Subsequently the mixture was stirred for 3 hours , and then left to stand overnight in the refrigerator and for 10 hours at laboratory temperature. The mixture was made alkaline with ammonia and was extracted several times with chloroform. The starting material was separated by column chromatography. The residue was suspended in acetqne and the crystals which formed were suction filtered.
M.p.: 240 to 242 °C.
Example 130 2- ( 2-Ethoxy- 5-methylsulfiny1-pheny1) - 1H- imidazo[ 4, 5-b] -pyridine Prepared analogously to Example 129 from 2-(2-ethoxy- 5-methylmercapto-phenyl)-lH-imidazo[ 4, 5-b]pyridine. M.p. : 197 to 198°C.
Example 131 2- [ 2- ( 2-Methylsulfiny1-ethoxy) - 5-methylmercapto-phenyl ]-1H- imidazo^, 5-b]pyridine Prepared analogously to Example 129 from 2- [2- (2-methylmercapto-ethoxy) - 5-methylmereapto-phenyl] - 1H-imidazo [ 4 , 5-b]pyridine hydrochloride. 2- ( 2-Ethoxy- 4-ethylsulfiny1-pheny1) - 1H- imidazo[ 4 , 5-b] -pyridine Prepared analogously to Example 129 from 2-(2-ethoxy- 4-ethylmercapto-phenyl)-lH- imidazo[4, 5-b]pyridine hydrochloride.
M.p.: 166 to 167°C.
Example 133 2-(2-Methoxy-4-propylsulfinyl-phenyl)-lH-imidazo[ 4, 5-bl-pyridine Prepared analogously to Example 129 from 2-(2-methoxy- 4-propylmercapto-phenyl)-lH- imidazo[4, 5-b] -pyridine hydrochloride.
M.p. : 182 to 183°C.
Exam le 134 2-(2-Ethoxy-4-propylsulfinyl-phenyl)-lH-imidazo[4, 5-bl-pyridine Prepared analogously to Example 129 from 2- (2-ethoxy- -propylmercapto-phenyl)-lH- imidazo[ 4, 5-b]pyridine hydrochloride.
M.p.: 182 to 183°C (decomp.).
Example 135 2-(2-Ethoxy-4-butylsulfinyl-phenyl)-lH-imidazo[4,5-b]-pyridine Prepared analogously to Example 129 from 2-(2-ethoxy- 4-butylmercapto-pheny1) - 1H- imidazo[ 4 , 5-b]pyridine hydrochloride.
M.p. : 185 to 186°C.
Example 136 2-( -Methylsulfonyl-phenyl)-lH-imidazo[4, 5-b]pyridine hydrochloride 6.95 g of 2-(4-methylmercapto-phenyl)-lH-imidazo[ 4, 5-b]pyridine hydrochloride were dissolved in 100 ml of glacial acetic acid, 8.5 g of 30% hydrogen peroxide were added and the mixture was left standing for 4 days at room temperature. After purification by passage through a silica gel column, the residue was dissolved in acetone and the hydrochloride was precipitated with methanolic hydrochloric acid.
M.p.: 286°C.
Example 137 2-(2-Ethoxy-4-ethylsulfonyl-phenyl)-lH-imidazo[ 4, 5-b]-pyridine 400 mg of 2-(2-ethoxy-4-ethylmercapto-phenyl)-lH-imidazo[4, 5-b] pyridine hydrochloride were dissolved in 30 ml of glacial acetic acid together with 0.5 ml of 30% hydrogen peroxide. The mixture was allowed to stand overnight and was then heated for 1 hour at 90°C.
After cooling, the mixture was diluted with water, neutralized with bicarbonate, extracted with chloroform and the organic layer was evaporated after drying. The residue was purified by column chromatography.
Example 138 2- ( 2-Methoxy- -propylsulfony1-pheny1) - lH-imidazo[ 4, 5-b]-pyrldine Prepared analogously to Example 137 from 2*- ( 2-methoxy- 4-propylmercapto-pheny1) - 1H- imidazo[ 4 , 5-b] -pyridine.
M.p.: 219 to 220°C.
Example 139 2- (2-Ethoxy-4-butylsulfony1-pheny1) - lH-imidazo[ 4, 5-b]-pyridine Prepared analogously to Example 137 from 2-(2-ethoxy- 4-butylmercapto-pheny1) - 1H- imidazo[ 4 , 5-b]pyridine. M.p.: 156 to 157°C.
Example 140 2-[2-Methoxy-4-(2-dimethylamino-ethoxy)-pheny1] - 1H-imidazo[ 4, 5-b]pyridine dihydrochloride a) 2- [ 2-Methoxy- 4- ( 2-chloroethoxy) -phenyl] - 1H-imidazo- [4, 5-b]pyridine hydrochloride 14 g of 2-methoxy-4- (2-hydroxyethoxy) -benzoyl morpholide were refluxed for 1½ hours with 7.1 g of 2 ,3-diaminopyridine in 100 ml of phosphorus oxychloride. Subsequently the mixture was decomposed with ice-water. The gradually crystallizing precipitate was suction filtered and washed with acetone.
M.p.: 266 to 268°C (decomp.). b) 2 g of 2-[2-methoxy-4-(2-chloroethoxy)-phenyl]-lH-imidazo[4,5-b] pyridine hydrochloride were heated in a closed vessel for 12 hours at 120°C with 5 g of dimethylamine in 100 ml of ethanol. After evaporation, the residue was purified by column chromatography.
The hydrochloride was precipitated from acetone with methanolic hydrochloric acid and subsequently recrystallized from methanol.
M.p. : ^> 250°C.
Example 141 2- [2-Methoxy-4- (3-dimethylamino-propoxy)-phenyl]-lH-imidazo^, 5-b]pyridine dihydrochloride Prepared analogously to Example 140 from 2- [2-methoxy- 4- (3-chloropropoxy) -phenyl]- 1H- imidazo [ 4 , 5-b] -pyridine hydrichloride.
M.p. : 238 to 242°C.
Exam le 142 2- [ 2-Methoxy- 4- ( 3-diethylamino-propoxy) -pheny1]- 1H-imidazo[4,5-b] pyridine dihydrochloride ~v ■ Prepared analogously to Example 140 from 2-[2-methoxy- 4- (3-chloropropoxy) -pheny1] - IH- imidazo[ 4 , 5-b] -pyridine hydrochloride..
M.p. : 222 to 224°C.
Example 143 2-* [ 2-Methoxy- 4- ( 3-piperidino-propoxy) -phenyl] - IH- imidazo-[4, 5-b]pyridine dihydrochloride Prepared analogously to Example 141 from 2- [2-methoxy-4- ( 3-chloropropoxy) -phenyl] - IH- imidazo-[4, 5-b]pyridine hydrochloride.
M.p.: 225 to 226°C (decomp.).
Example 144 2- [ 2-Methoxy- 4- ( 3- ( 4-pheny1-piperazin- l-y1) -propoxy) -phenyl ]- IH- imidazo[ 4 , 5-b]pyridine dihydrochloride Prepared analogously to Example 141 from 2- [2-methoxy- 4- ( 3-chloro-propoxy) -pheny1] - IH-imidazo[ 4, 5-b]-pyridine hydrochloride.
M.p. : 197, to 200°C.
Example 145 2-Γ2-Methoxy- 4- ( 3- ( 4- ( 2-methoxypheny1) -piper/fin- 1-yl) -propoxy) -pheny1] - IH- imidazo[ 4, 5-b] -pyridine trihydrochloride hydrate Prepared analogously to Example 141 from 2-[2-methoxy- - ( 3-chloro-propoxy) -phen l] - 1H- imidazo [ 4 , 5-b]-pyridine hydrochloride.
M.p.: Sintering from 180°C.
Example 146 2- ( 2 , 6-Dichloropheny1) - 1H- imidazo[ 4 , 5-b]pyridine hydrochloride Prepared analogously to Example 120 from 2 ,6-dichlorobenzoic acid. Purification by column chromatography.
M.p.: 262 to 264PC (decomp.).
Example 1A7 2- (2-Methoxy-4-morpholino-phenyl) -lH- imidazo^, 5-b]-pyridine hydrochloride a) 2- ( 2-Methoxy- 4-morpholino-pheny1) - 1 , 3-dithiolanium-iodide 10.5 g of 3-morpholino-anisole and 15.7 g of 2-methylmercapto-1 ,3-diethiolanium-methyl sulfate were boiled in a mixture of 60 ml of glacial acetic acid and 8.3 ml of pyridine fpr 1 hour. After cooling, the mixture w¾s poured into a saturated potassium iodide solution. The red precipitate was suction filtered and washed with water. The product was used without further purification. b) 22 g of 2-(2-methoxy-4-morpholino-phenyl)-l,3-dithiol anium. iodide , 10.9 g of 2 ,3-diaminopyridine and 60 ml of glycol were heated for 2 hours at 130°C. After cooling, water was added and the mixture was extracted with chloroform. After evaporation, the residue was purified by column chromatrography and the hydrochloride was precipitated from acetone with ether/hydrochloride acid.
M.p.: 207 to 209°C (decomp.).
Example 148 2- [ 2-Methoxy^ 4- ( 4-methy1-piperazin- 1-y1) -phenyl ] - 1H-imidazo[4, 5-b] pyridine dihydrochloride Prepared analogously to Example 147 from 3-(4-methyl-pip.erazin-i-yl)-anisole.
M.p. : 279 to 282°C.
Example 149 · 2- [ 2-Methoxy- 4- ( 4-ethy1-piperazin- 1-y1) -phenyl] - 1H-imidazb[4, 5-b]pyridine dihydrochloride Prepared analogously to Example 148 from 3-(4-ethyl-piperazin-l"'yl)-anisole.
M,p. : 218 to 222°C.
Example 150 2- [2-Methoxy- 4- ( -propyl-piperazin- l-y1) -phenyl ]- 1H-imidazo[ 4, 5-b]pyridine dihydrochloride Prepared analogously to Example 147 from 3- (4-propyl-piperazin- l-yl)-anisole.
M.'p. : 256 to 258°C.
Example 151 2- [2-Ethoxy- 4- ( 4-methy1-piperazin- l-y1) -phenyl] - 1H-imidazo^, 5-b]pyridine dihydrochloride Prepared analogously to Example 147 from 3-(4-methyl-^piperazin- l-y1) - 1-ethoxybenzene .
M.p.: 269 to 271°C.
Example 152 2- ( 2-Ethoxy-4- (4-ethyl-piperazin- 1-yl) -phenyl ] - 1H-imidazoC 4, 5-b .] -pyridine dihydrochloride Prepared analogously to Example 147 from 3- ( 4-ethyl-piperazin- l-y1) - 1-ethoxybenzene .
M.p. : 257 to 259°C.
Exam le 153 2- [ 2-Methoxy- 4- ( 4-phenyl-piperazin- l-y1) -phenyl]- 1H-imidazo[ 4, 5-b]pyridine dihydrochloride Prepared analogously to Example 147 from 3-(4-pheny1-piperazin- l-yl-anisole. Μ,.ρ. : 217 to 219°C.
"V.
Example 154 2 -[ 4-Methoxy- 2- ( 2-morpho1ino-ethoxy) -pheny1] - 1H-imidazo[4> 5-b]pyridine Prepared from 6.3 g of 2-[4-methoxy-2-(2-chloro-ethoxy) -phenyl]- lH-imidazo[ 4, 5-b]pyridine by refluxing for 3 hours in 60 ml of morpholine, distilling off the excess of morpholine in vacuo and recrystallizing the residue from isopropanol.
M.p. : 188 to 190°C.
Example 155 2- [ 4-Methoxy- 2- (3- ( -phenyl^piperazin- 1-y1) -propoxy) -phenyl] - 1H- imidazo [ 4, 5-b]pyridine 10 g of 2-[4-methoxy -2-(3-chloropropoxy)-phenyl]-lH-imidazo[4,5-b]pyridine, 10.2 g of 1-phenyl-piperazine and 5 g of potassium carbonate were refluxed for 8 hours in 100 ml of ethanol. After distilling off the ethanol in vacuo, the mixture was recrystallized from ethanol/water 3:1.
M.p. : 162 to 163°C.
Example 156 2- [ 4-Methoxy- 2- ( 3- ( 2-pheny1-ethylamlno) -propoxy) -pheny1] -lH-imidazo^4, 5-b¾>yridine dihydrochloride Prepared by heating 1.77 g of 2-[4-methoxy-2- ( 3-chloropropoxy) -phenyl] - 1H- imidazo[ 4 , 5-b]pyridine in 10 ml of 2-phenyl-ethylamino for 1¾ hours at 180°C.
The free base was converted into the dihydrochloride with methanolic hydrochloric acid. Recrystallization from isopropanol.
M.p. : 238°C.
Example 157 2- [ -methoxy- 2- ( 3- (N-methy1-N- 2-phenylethyl-amino) -propoxy) -phenyl] -lH-imidazo[ 4, 5-b]pyridine dihydrochloride Prepared from 3.2 g of 2- [4-methoxy- 2- (3-chloropropoxy) -phenyl] - 1H- imidazo[ 4, 5-b]pyridine and 2.7 g of N-methy1-2-pheny1-ethylamine by heating for 6 hours in ethanol at 120°C in a closed vessel. The dihydrochloride was precipitated with ethereal hydrochloric acid from an ethyl acetate solution of the base, purified by column chromatography and recrystallized from isopropanol. M.p. : 212 to 215°C.
Example 158 2- [ 4-Methoxy-2- ( 3- (N-methy1-N- ( 2- (3.4-dimethoxyphenyl) -ethyl) -amino) -propoxy) -phenyl] - 1H- imidazo[ 4 , 5-b]-pyridine dihydrochloride - Prepared from 5.0 g of 2-[4-methoxy-2-(3-chloro-propoxy) -phenyl]- 1H-imidazo[ 4, 5-b]pyridine and 8.5 g of -[2-(3 ,4-dimethoxy-phenyl) -ethyl ]-methylamine by refluxing for 12 hours in ethylene glycol monomethyl . ether. Precipitation of the dihydrochloride from ethyl acetate with ethereal hydrochloric acid.
M.p. : 169°C.
Example 159 2- [ 4-Methoxy-2- ( 3-thiomorpholino-propoxy) -phenyl] - 1H-imidazo[4> 5-b]pyridine Prepared analogously to Example 158 from 2-[4" methoxy- 2- ( 3-^chloropropoxy) -phenyl]- 1H- imidazo[ 4, 5-b] pyridine and thiomorpholine by heating for 30 hours. Purification was by precipitation of the maleate from ethyl acetate solution. The free base was obtained from the maleate with 2N ammonia.
M.p. : 111°C.
Example 160 2- Γ4-Methoxy- 2- ( 2- ( 4-methy1-piperazin- 1-y1) -ethoxy) ÷ pheny1] 1H-imidazo[ 4, 5-bJpyridine Prepared from 3.0 g of ,2-[4-methoxy-2-(2-chloro-etho>iy)-phenyl]-lH-imidazo[4,5-b]pyridine and 2.0 g of N-methylpiperazine by refluxing for 40 hours in ethanol. After purification by column chromatography over silica gel, the product was recrystallized from water.
M.p. : 136 to 137 °C .
Example 161 2- [ 4-Methoxy- 2- ( 3- ( A- ( 2-phenylethy 1) -piperazin- 1-y 1) -propoxy)-phenyl]-lH-imidazo[ 4 > 5-b]pyridine tri-hydrochloride Prepared analogously to Example 157 from 2- [ 4-methoxy- 2- ( 3-chloro-propoxy) -phenyl] - 1H- imidazo[ 4 , 5-b]-pyridine and l-( 2-pheny 1-ethyl) -piperazine.
M.p. : 236 to 238 °C .
Example 162 2- [ 4-Methoxy- 2- ( 3-methylamino-propoxy) -phenyl] - 1H-imidazo[ 4 , 5-b]pyridine hydrochloride Prepared analogously to Example 157 from 2r [ 4-methoxy- 2 - ( 3-chloropropoxy) ?-pheny 1 ] - 1H- irnidazo[ 4 , 5-b]-pyridine and methylamine.
M.p.: 215°G .
Example 163 2- [ 4-Methoxy- 2- ( 2-dimethylamino-ethoxy) -phenyl] - 1H-imidazo[ 4 > 5-b]pyridine dihydrochloride - 9 - Prepared analogously to Example 157 from 2-[4-methoxy-2-(2-chloro-ethoxy)-phenyl]-lH-lmidazo[4,5-b]-pyridine and dimethylamine.
M.p. : 240 to 242°C.
Example 164 .ι Τ ' . . 2- ( 2-Methylamino-pheny1) - 1H- imidazo[ 4, 5-b]pyridine 1.77 g of N-methyl-lsatinoyl anhydride and 1.09 g of 2 ,3-diaminopyridine were melted and heated for 10 minutes at 180°C. Recrystallization from ethyl acetate. M.p. : 262 to 263°C.
Example 165 2- (2 ,4-Dimethoxy-phenyl)-3-(2-phenyl-ethyl)-3H-imidazo-[4,5-b]pyridine 0.17 g of 2-(2nhydroxy-4-methoxy-phenyl)-3-(2-phenyl-ethyl)-3H-imidazo[4,5-b]pyridine were dissolved in 7 ml of dimethylformamide. The mixture was stirred for 5 minutes with 0.02 g of sodium hydride (80% suspension in oil) and reacted with 0.07 g of methyl iodide under ice-cooling. After 4 hours, water was added to the reaction mixture. The precipitated product was dissolved in ethyl acetate, and the organic layer was washed with 2N sodium hydroxide solution and water and evaporated.
Recrystallization from ethanol/water.
M.p. : 157°C.
Example 166 2- ( 2 , 4-Dimethoxy-phenyl) -3- [ 2- ( 3 , 4-dimethoxy-pheny1) -e hyl]i3H-imidazo.[4> 5-b]pyridine. hydrochloride Prepared analogously to Exampie 120 from 3-amino-2-[2-(3 , 4-dimethoxy-phenyl)-ethylamino]pyridine and 2,4-dimethoxy-benzoic acid. The hydrochloride was precipitated from ether.
M.p. : 195°C.
Example 167 2- ( 2-Fluoro- 5-methylmercapto-pheny1) - lH-imidazo [ 4 , 5-b] -pyridine Prepared analogously to Example 120 from 2,3-diaminopyridine and 2-fluoro- 5-methylmercapto-benzoic acid M.p. : 195°C.
Example 168 2-(2-Fluoro-5-methylsulfinyl-phenyl)-lH-imidazor4t5-b]-pyridjne Prepared from 2- ( 2·* fluoro- 5-methylmercapto-pheny1) -lH-imidazo[4,5-b]pyridine by oxidation with hydrogen peroxide iri glacial acetic acid at room temperature.
The purification was effected by column chromatography on silica gel with chloroform/methanol 19:1 as eluent.
M.p. : 190 to 192°C.
Exam le 169 2·^ (2-Fiuoro-,5-methylsulfonyl-phenyl)-lH-imidazo[4> 5-b]-pyrldine Prepared from 2<-(2-fluoro-5-methylmercapto-phenyl)-iH-imidazo[ ,5-b]pyridine according to Example 168, but at 40°C.
M.p. : 242°C.
Example 170 2- ( 3 , 4 Dimeth xyphenyl)-3-(3-morpho1ino-propy1) -3H- imid zo" [4,5-b]pyridine dihydrochloride a) .N- ( 2-Chloro-3-pyridy1) -N ' - ( 3-mprpholinopropy1) -3 , 4- dimethoxy-benzamidine 4.9 g of N- (3-morpholinopropy1)-3 ,4-dimethoxy-benzamide and 2.04 g of 2-chloro-3-aminopyridine were refluxed for 2 hours in 85 ml of phosphorus oxychloride. After distilling pff the excess pf phosphorus oxychloride, the mixture was poured into water, .-The solution was made alkaline and extracted with ethyl acetate. After Prepared analogously to Example 120 from 2- chlorobenzoic acid and 2 ,3-diaminopyridine.
M.p. : 233°C.
Example 183 2- (2-Fluoro^4-methy1stjlfiny1-pheny1) - 1H-imidazo[ , 5-b1- pyridlne Prepared analogously to Example 168 from 2-(2- fluoro-4-methy1-mercapto-pheny1) - 1H- imidazo [ 4 , 5-b] -pyridine. Crystallization by trituration in petroleum ether.
M.p. : 219°C.
Example 184 2-( 4-Methylmercapto-phenyl)-3-(3-morph0lino-propyl)-3H-imidazo[4f 5-b]pyridine Prepared analogously to Example 170 from N- ( 2^ch1orό-3-pyridy1) -N ' - ( 3-morphp1ino-propy1) - 4-meth 1-mercapto-benzamidine. Recrystallized from ether/ cyclohexane.
M.p. : 110°C.
Example 185 2-(4-Methyl-phenyl)-3-(3-morpholino-propyl)-3H-imidazo-[4,5-bjpyridine hydrochloride Prepared analogously to Example 170 from N-(2-chloro-3-pyridyl)-N'-(3-morpholino-propyl) -4-methy1-benzamidine in dimethylsulfoxide with potassium tert . -butoxide. ' M.p. : 238°C.
Example 186 2-[2-Propoxy-4-(4-methyl-plperazin-l-yl)-phenyl]-lH- Imidazo[ 4, 5-b]pyrldlne dlhydrochloride Prepared analogously to Example 147 from 3-(4- methyl-piperazin-l-yl)-l-propoxy-benzene. ^ , M.p. : 237 to 238°C.
Example 187 Tablets containing 100 mg of 2- (2 j 4-dimethoxy-phenyl) - 1H- imidazoC 4 , 5-b]pyridine hydrochloride Composition: 1 tablet contains: Active ingredient 100.0 mg lactose 50.0 mg polyvinyl pyrrolidone 5.0 mg carboxymethylcellulose 19.0 mg magnesium stearate 1.0 mg 175.0 mg moist screening: 1.5 mm Drying: in the circulating air drier at 50°C.
Dry screening: 1 mm The dry granulate was admixed with. the remaining auxiliary products and pressed into tablets.
Weight of tablet: 175 mg Punch: 8 mm 0 Example 188 Coated tablets containing 50 mg of 2-(2 ,4-dimethoxy phenyl)-lH-imidazo[ A, 5-b]pyridine hydrochloride 1 coated tablet core contains: Active ingredient corn starch, dried soluble starch carboxymethyIce1lulo magnesium stearate 80.0 mg < The active ingredient and corn starch were homogeneously moistened with the aqueous solution of the soluble starch.
Moist screening: 1.0 mm Dry screening: 1.0 mm Drying: at 50°C in the circulating air drier The granulate and the remaining auxiliary products were mixed and pressed to form coated tablet cores.
Weight of core: 80 mg Punch: 6 mm, arched (5 mm) The finished cores were covered with a coat consisting essentially of sugar and talcum in conventional manner. The finished coated tablets were polished with beeswax.
Weight of the coated tablet: 120 mg Example 189 Suppositories containing 75 mg of 2-(2,4-dimethoxy-phenyl)- 1H-imidazo [ , 5-b]pyridine hydrochlor ide 1 suppository contains: Active ingredient 75.0 mg suppository mass (e.g. Witepsol H 19 and Witepsol W 45) 1 625.0 mg 1 700.0 mg Method of preparation: The suppository mass was melted. At 38°C the pulverized active ingredient was homogeneously dispersed in the melt. The suppository mass was cooled to 35°C and poured into pre-cooled moulds.
Weight of suppository: 1.7 g Example 190 Ampoules containing 50 mg of 2-(2 , 4-dimethoxy-phenyl) - 1H-imidazo[ 4, 5-b]pyridine hydrochloride 1 ampoule contains: , Active ingredient 50.0 mg sorbitol 250.0 mg distilled water ad 5.0 ml -X Method of preparation; The active ingredient and the sorbitol were dissolved in distilled water. The solution was made up to the given volumn and filtered sterile.
Filling: into ampoules of 5 ml capacity Sterilisation: 20 minutes at 120°C.
Example 191 Drop solution containing 25 mg of 2-(2 ,4-dimethoxy-phenyl)-lH-imida2o[ >5-b]pyridine hydrochloride per 5 ml Active ingredient 5.0 g methyl p_-hydroxybenzoate 0.035 g propyl p_-hydroxybenzoate 0.015 g aniseed oil 0.05 g menthol 0.06 g sodium saccharine 1.0 g glycerine 10.0 g ethanol 40.0 g distilled water ad 100.0 ml Method of preparation: The benzoic acid esters were dissolved in ethanol and subsequently the aniseed oil and the menthol were added. Active ingredient, glycerine and sodium saccharine were dissolved in water and added, solution was filtered pure.

Claims (55)

1. Ill- 44127/3 [wherein R^, R2 and R^, which may be the same or different, each represents a hydrogen or halogen atom; a hydroxy, alkyl, allyloxy, benzyloxy, alkylthio, alkylsulfinyl or alkylsulfonyl group; an amino group optionally substituted by one or two alkyl groups; a morpholino or a piperazino group optionally substituted in the 4-position by a phenyl group or an alkyl group containing from 1 to carbon atoms, or an alkoxy group containing from 1 to 4 carbon atoms, optionally substituted by a halogen atom or by a hydroxy, alkoxy, alkylthio, alkylsul inyl,. alkylsulfonyl, alkylamino, dialkylamino, piperidino, morpholino, thiomorpholino, thiomorpholino-S-oxide , thiomorpholino-S,S-dioxide, 4-methyl- piperazino, 4-phenylpiperazino, 4-dimethoxyphenylpiperazino, 4-phenylethylpiperazino, phenylethylaraino, N-meth l-phenyl- ethylaraino or N-methyl-dimethoxyphenylethylamino group; or two of the groups R-^to R^ together represent a methylenedioxy group and the remaining R^, R^ or R^ group is as hereinbefore 44127/2 from -1 to 4 carbon atoms; with the proviso that, if any two of the groups R^, anfi-'R^ represent hydrogen atoms, then the other group is other than a hydrogen or a halogen atom, or a. methyl or amino group. R^ represents a hydrogen atom; an alkyl group optionally substituted by a hydroxy, dialkylamino, phenyl, dimethoxyphenyl , piperidino, rnorpholino, 4-methyl- piperazino or 4-phenylpiperazino group, each of the above mentioned alkyl groups containing from 1 to 4 carbon atoms, or a phenyl group optionally substituted by one or more halogen atoms or methoxy groups, with the^proviso that when represents a hydrogen atom at least one of the groups to R^ is other than hydrogen; and Rj. represents a hydrogen atom, a halogen atom or „ a lower alkyl group and the corresponding imidazo[ , 5b] pyridine-N-oxides and isomers thereof and acid addition salts thereof.
2. Compounds of general formula la wherein R^, R^, R^ and R^ are as defined in claim land R^ represents a hydrogen atom.
3. Compounds of general formula I wherein R^ to R^ are as defined in claim 1.
4. Compounds of general formula I and isomers thereof of general formula la [wherein R^, R^ and R^ represent hydrogen atoms and R^ and R^, which may be the same or different, each represents a halogen atom or a methyl, methoxy, ethoxy, alkylthio, aIky1sulfiny1, dialkylamino- ί,- piperazinoalkoxy , 4-phenylpiperazinoalkoxy or alkyl-sulfinylalkoxy group (wherein each alkyl group contains from 1 to 3 carbon atoms and each alkoxy group contains 2 or 3 carbon atoms)] and physiologically compatible acid addition salts thereof.
5. 2-(2,4-Dimethoxy-phenyl)-lH-imidazo[4,5-b]pyridine and physiologically compatible acid addition salts thereof.
6. 2-(2-Methoxy-4-methylmercapto-phenyl)-lH-imidazo-[4,5-b]pyridine and physiologically compatible acid addition salts thereof.
7. 2- ( 2-Methoxy-4-methylsu]finyl-phenyl) - 1H- imidazo[ 4 , 5-b] -pyridine and physiologically compatible acid addition salts thereof .
8.. 2-(2-Methoxy-4-methyl-phenyl)-lH-imidazo[4,5-b]pyridine and physiologically compatible acid addition salts thereof.
9. 2- (2-Methoxy-5-methylmercapto-phenyl)-lH- imidazole4, 5-b]pyridine and physiologically compatible acid addition salts thereof .
10. 2- ( 2-Ethoxy-4-methy1-phenyl ) -lH-imidazo[ 4 , 5-b]pyridine and physiologically compatible acid addition salts thereof.
11. Compounds of general formula 44127/2 Ί and isomers thereof of general formula [wherein R^, and R^, which may be the same or different, each represents a hydrogen or halogen atom; a hydroxy, allyloxy, benzyloxy, alkylthio, alkylsulfinyl or alkyl- sulfonyl group; an amino group optionally substituted by one or two alkyl groups; or an alkoxy group containing from 1 to 4 carbon atoms optionally substituted by a halogen atom or by a hydroxy, alkoxy, alkylthio, alkyl¬ sulfinyl, alkylsulfonyl , alkylamino, dialkylamino, morpholino, thiomorpholino , N-methylpiperazino or N- phenylpiperazino group; or two of the groups R^ to R^ together represent a methylenedioxy group and the remaining R^ , 2 or R^ group is as defined above; each of the above mentioned alkyl groups containing from 1 to 4 carbon atoms; with the proviso that, if any two of the groups R^ , R2 and R- represent hydrogen atoms, then the other group is other than a hydrogen or a halogen atom, or a methyl or amino group; R^ represents a hydrogen atom; an alkyl group optionally substituted by a hydroxyl , dialkylamino, phenyl or morpholino group, whereby each of the above mentioned alkyl groups contains from 1 to 4 carbons; or a phenyl group optionally substituted by a halogen atom or a methoxy group; with the 44127/2 and Rj. represents a hydrogen or halogen atom or a lower alkyl group] and physiologically compatible acid addition salts thereof .
12. Compounds of general formula and isomers thereof of general formula [wherein Rl , R2 and R^, which ma be the same or different, each represents a hydrogen, fluorine or chlorine atom, a methyl or rnethyl-amino group, or an alkoxy group containing from 2 to 4 carbon atoms substituted by a dimethylamino , diethylamino , piperidino, morpholino, thiomorpholino , phenylethylamino , N-methylphenylethylamino or N-methyl-dimethoxyphenylethylamino group or by a piperazino group substituted in the 4-position by a methyl, phenyl, di-methoxyphenyl or phenylethy1 group; with the proviso that, if any two of the groups , and represent hydrogen atoms , then the other group is other than a hydrogen or a halogen atom, or a methyl or amino group; R^ represents a hydrogen atom, an alkyl group containing phenylpiperazino group; with the proviso that when represents a hydrogen atom at least one of the groups to R^ is other than hydrogen; and R,. represents a hydrogen atom] and physiologically compatible acid addition salts thereof .
13. Compounds as claimed in claim 1 other than those claimed in claims 5 to 10 as herein specifically described.
14. Compounds as claimed in claim 11 other than those claimed in claims 5 to 10 as herein specifically described.
15. Compounds as claimed in claim 12 as herein specifically described.
16. A process for the preparation of compounds of general formula I and iosmers thereof of general formula la as defined in claim 1 which comprises reacting a compound of formula [wherein R,. is as defined in claim 1 and Y represents a group of formula R^NH-(wherein R^ is as defined in claim 1)] with a compound of formula - Ill - (wherein to are as defined in claim 1 arid X, represents a carboxyl, thiocarboxyl or dithiocarboxyl group) or a functional derivative thereof.
17. A process as claimed in claim 16 wherein the functional derivative is an acid halide, anhydride, ester or orthoester.
18. A process for the preparation of compounds of general formula I and isomers thereof of general formula la as defined in claim 1 which comprises reacting a compound of formula [wherein R. to R~ are as defined in claim 11 and X represents an appropriate -NR^- containing group (wherein is as defined in claim 1) which is derived from a carboxyl, thio-carboxyl or dithiocarboxyl group] .
19. A process as claimed in claim 18 wherein the said - R^- containing group is a nitrile, amide, amido ester, imido thioester, imido halide or amidine group.
20. A process as claimed in any of claims 16 to 19 wherein the reaction is effected in the presence of a solvent .
21. A process as claimed in any of claims 16 to 20 wherein the reaction is effected at temperatures from -20 to 250°C.
22. A process as claimed in either claim 16 or claim 18 wherein a compound of formula III wherein X represents a carboxyl or an amide group is reacted with a compound of formula II as defined in claim 16 or claim 18 respectively in the presence of phosphorus oxychloride or thionyl chloride and in the presence of pyridine or triethylamine at temperatures from -20 to 120 °C.
23. A process as claimed in claim 18 wherein a compound of formula III wherein X represents a nitrile group is reacted with a compound of formula II as defined in claim 18 in the presence of a catalytic quantity of p-toluene-sulfonic acid and at temperatures from 120 to 180 °C.
24. A process as claimed in claim 18 wherein a compound of formula III wherein X represents a thioamide group is reacted with a compound of formula II as defined in claim 18 at temperatures from 100 to 150 °C.
25. A process as claimed in claim 18 wherein a compound of formula II wherein Y represents a chlorine atom is reacted with a compound of formula III as defined in claim 18 at temperatures from 100 to 200 °C.
26. A process for the preparation of compounds of general formula I and isomers thereof of general formula la as defined in claim 11 which comprises reacting a compound of formula [wherein is as defined in claim 11 and Y represents a group of formula R^NH- (wherein R^ is as defined in claim 11)] with a compound of formula (wherein R^to R^ are as defined in claim 11 and X represents a carboxyl, thiocarboxyl or dithiocarboxyl group) or with a functional derivative thereof.
27. A process for the preparation of compounds of general formula I and isomers thereof of general formula la as defined in claim 12 which comprises reacting a compound of formula [wherein R,. represents a hydrogen atom and Y represents a group of formula R^NH- (wherein R^ is as defined in claim 12)] with a compound of formula (wherein R^ to R^ are as defined in claim 12 and X represents a carboxy, thiocarboxy or dithiocarboxy group) or with a functional derivative thereof.
28. A process for the preparation of compounds of general formula I and isomers thereof of general formula la as defined in claim 11 which comprises reacting a compound of formula (wherein Rg is as defined in claim 11 and Y represents a [wherein R^ to are as defined in claim 11 and X represents an appropriate - R^- containing group (wherein R. is as defined in claim 11) which is derived from a 4 carboxyl, thiocarboxyl or dithiocarboxyl group].
29. A process for the preparation of compounds of general formula I and isomers thereof of general formula la as defined in claim 12 which comprises reacting a compound of formula (wherein R,. represents a hydrogen atom and Y represents a halogen atom) with a compound of formula [wherein R to ^ are as defined in claim 12 and X represents an appropriate - R^- containing group (wherein R^ is as defined in claim 1) which is derived from a carboxyl, thiocarboxyl or dithiocarboxyl group] . )
30. A process as claimed in any of claims 16 to 25 wherein a compound of formula I or la containing a reactive halogen atom thereby obtained is subsequently converted into the corresponding amino compound by reaction with an amine.
31. A process as claimed in any of claims 16 to 25 and 30 wherein a compound of formula I or la containing a reacting hydrogen atom thereby obtained is subsequently alkylated by reaction with an alkylating agent in the presence of a. base .
32. A process as claimed in any of claims 16 to 25, 30 and 31 wherein a compound of formula I or la thereby obtained is subsequently converted into the corresponding N-oxide, S-oxide or S,S-dioxide compound by means of an oxidising agent.
33. A process as claimed in any of claims 16 to 25 and 30 to 32 wherein a compound of formula I or la thereby obtained is subsequently converted into a acid addition salt thereof .
34. A process as claimed in claim 33 wherein the compound of formula I or la is converted into a physiologically compatible acid addition salt thereof.
35. A process as claimed in any of claims 30 to 34 wherein the compound of formula I or la is as defined in claim 11.
36.. A process as claimed in any of claims 30 to 34 wherein the compound of formula I or la is as defined in claim 12.
37. A process for the preparation of compounds of general formula I and isomers thereof of general formula la and the corresponding imidazo[ 4, 5-b]pyridine-N-oxides and isomers thereof as defined in claim 1 substantially as herein described.
38. A process for the preparation of compounds of general formula I and isomers thereof of general formula la as defined in claim 11 substantially as herein described.
39. A process for the preparation of compounds of general formula I and isomers thereof of general formula la as defined in claim 12 substantially as herein described.
40. A process for the preparation of compounds of general formula I ad isomers thereof of general formula la and the corresponding imidazo[4,5-b]pyridine-N-oxides and isomers thereof as defined in claim 1 substantially as herein described with reference to Examples 1 to 186.
41. A process for the preparation of compounds of general formula I and isomers thereof of general formula la as defined in claim 11 substantially as herein described
42. A process for the preparation of compounds of general formula I and isomers thereof of general formula la as defined in claim 12 substantially as herein described with reference to Examples 120 to 186.
43. Compounds of general formula I and isomers thereof of general formula la and the corresponding imidazo[4,5-b] pyridine-N-oxides and isomers thereof as defined in claim 1 and acid addition salts thereof whenever prepared by a process as claimed in any of claims 16 to 25, 30 to 34, 37 and 40.
44. Compounds of general formula I and isomers thereof of general formula la as defined in claim 11 and physio¬ logically compatible acid addition salts thereof whenever prepared by a process as claimed in any of claims 26, 28, 35, 38 and 41.
45. Compounds of general formula I and isomers thereof of general formula la as defined in claim 12 and physio¬ logically compatible acid addition salts thereof whenever prepared by a process as claimed in any of claims 27, 29, 36, 39 and 42.
46. Pharmaceutical compositions comprising as active ingredient at least one compound of formula I or isomer thereof of formula la or physiologically compatible acid addition salt thereof in association with a pharma¬ ceutical carrier or excipient. 44127/2
47. Compositions as claimed in claim 46 in a form suitable for oral, rectal or parenteral administration.
48. Compositions as claimed in claim 47 in the form of tablets, coated tablets, suppositories, ampoules or drops .
49.' Compositions as claimed in any of claims 46 to 48 in the form of dosage units.
50.. Compositions as claimed in claim 49 wherein each dosage unit contains -from~35 to 200-mg of active ingredient
51. Compositions as claimed in claim 50 wherein each dosage unit contains from 50 to 100 mg of active ingredient
52. Compositions as claimed in claim 46 containing as active ingredient a compound as claimed in claim 11.
53. Compositions as claimed in claim 46 containing as active ingredient a compound as claimed in claim 12.
54. Compositions as claimed in claim 46 substantially as herein described.
55. Compositions as claimed in claim 46 substantially as herein described with reference to Examples 187 to 191.
IL44127A 1973-02-03 1974-02-01 Imidazo(4,5-b)pyridines their preparation and pharmaceutical compositions containing them IL44127A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2305339A DE2305339C3 (en) 1973-02-03 1973-02-03 Imidazo [4,5-b] pyridines, their preparation and their use as cardiotonica
DE2361757A DE2361757A1 (en) 1973-12-12 1973-12-12 Cardioactive imidazopyridines - substd. 2-phenyl 1H(or3H) imidazo (4,5,6) pyridines with positive inotropic and platelet aggregation inhibiting activity

Publications (2)

Publication Number Publication Date
IL44127A0 IL44127A0 (en) 1974-05-16
IL44127A true IL44127A (en) 1977-05-31

Family

ID=25764640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL44127A IL44127A (en) 1973-02-03 1974-02-01 Imidazo(4,5-b)pyridines their preparation and pharmaceutical compositions containing them

Country Status (24)

Country Link
JP (1) JPS5748556B2 (en)
AT (1) AT332873B (en)
BG (1) BG23902A3 (en)
CA (1) CA1041502A (en)
CH (1) CH605939A5 (en)
CS (1) CS200169B2 (en)
DD (1) DD108989A5 (en)
DK (1) DK140760B (en)
ES (1) ES422450A1 (en)
FI (1) FI58126C (en)
FR (1) FR2215968B1 (en)
GB (1) GB1445824A (en)
HK (1) HK4080A (en)
HU (1) HU170909B (en)
IE (1) IE39066B1 (en)
IL (1) IL44127A (en)
NL (1) NL173645C (en)
NO (1) NO139386C (en)
PH (1) PH14988A (en)
PL (1) PL93127B1 (en)
RO (2) RO79057A (en)
SE (1) SE411451B (en)
SU (2) SU563917A3 (en)
YU (2) YU36955B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS49109394A (en) * 1973-02-27 1974-10-17
DE3132754A1 (en) * 1981-08-19 1983-03-03 Merck Patent Gmbh, 6100 Darmstadt 2-Arylimidazo[4,5-b]pyridines, pharmaceutical preparations containing these compounds, and processes for their preparation
ES517193A0 (en) * 1981-11-10 1983-12-01 Wellcome Found A PROCEDURE FOR THE PREPARATION OF NEW IMIDAZO DERIVATIVES (4,5-C) PIRIDINA.
RO86850B (en) * 1982-05-03 1985-05-31 Eli Lilly And Company Process for the preparation of 2-phenylimdazo [4,5 c] pyridines
US4772600A (en) * 1986-06-09 1988-09-20 A. H. Robins Company, Inc. Fused imidazoheterocyclic compounds and pharmaceutical compositions
JPH01190663A (en) * 1988-01-22 1989-07-31 Terumo Corp Cysteamine derivative and antirheumatic agent containing said derivative
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
JP6173693B2 (en) * 2010-02-24 2017-08-02 リサーチ・トライアングル・インスティチュート Aryl piperazine opioid receptor antagonist
BR122019003178B1 (en) * 2010-12-24 2020-04-28 Sumitomo Chemical Co pest control method
WO2013191189A1 (en) * 2012-06-21 2013-12-27 住友化学株式会社 Fused heterocyclic compound
EP2865672A4 (en) 2012-06-22 2015-12-16 Sumitomo Chemical Co Fused heterocyclic compound

Also Published As

Publication number Publication date
NO139386C (en) 1979-02-28
SU634673A3 (en) 1978-11-25
FR2215968B1 (en) 1977-01-28
CH605939A5 (en) 1978-10-13
AU6512974A (en) 1975-08-07
RO84276B (en) 1984-07-30
IE39066B1 (en) 1978-08-02
YU36955B (en) 1984-08-31
IL44127A0 (en) 1974-05-16
CS200169B2 (en) 1980-08-29
GB1445824A (en) 1976-08-11
DD108989A5 (en) 1974-10-12
YU110480A (en) 1982-06-18
PH14988A (en) 1982-03-12
YU17674A (en) 1982-06-18
HU170909B (en) 1977-09-28
JPS5748556B2 (en) 1982-10-16
SE411451B (en) 1979-12-27
PL93127B1 (en) 1977-05-30
ES422450A1 (en) 1976-05-01
NO740327L (en) 1974-08-06
DK140760C (en) 1980-04-21
BG23902A3 (en) 1977-11-10
RO84276A (en) 1984-05-23
AT332873B (en) 1976-10-25
SU563917A3 (en) 1977-06-30
FI58126C (en) 1980-12-10
ATA16474A (en) 1976-02-15
JPS49102693A (en) 1974-09-27
NL7401254A (en) 1974-08-06
YU36956B (en) 1984-08-31
IE39066L (en) 1974-08-03
NO139386B (en) 1978-11-20
DK140760B (en) 1979-11-12
FI58126B (en) 1980-08-29
HK4080A (en) 1980-02-08
RO79057A (en) 1982-06-25
NL173645C (en) 1984-02-16
CA1041502A (en) 1978-10-31
FR2215968A1 (en) 1974-08-30
NL173645B (en) 1983-09-16

Similar Documents

Publication Publication Date Title
JP4145955B2 (en) Pyrrolo [2,3-d] pyrimidine and use thereof
US8980887B2 (en) 2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and uses thereof
US3985891A (en) 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof
FI79312B (en) FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA 2-PHENYL-1H-IMIDAZO- / 4,5-C / PYRIDINER OCH N-OXIDER OCH SYRA-ADDITIONSSALTER DAERAV.
US5614518A (en) Morpholine derivatives as dopamine receptor subtype ligands
JP2003528096A (en) Decahydro-isoquinoline
IL44127A (en) Imidazo(4,5-b)pyridines their preparation and pharmaceutical compositions containing them
TWI336253B (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
PL125321B1 (en) Process for preparing novel,condensed derivatives of pyrimidines
FI68835C (en) PROCEDURE FOR THERAPEUTIC ADMINISTRATION OF THERAPEUTIC 4-MINOACYL-1,4,9,10-TETRAHYDROPYRAZOLO (4,3-B) (1,5) BENZODIAZ EPN-10-ONER
US4110455A (en) 6-aryl-s-triazolo-(4,3-a)-pyrido-(2,3-f)-1,4-diazepines
CS207619B2 (en) Method of making the new derivatives of 5,11-dihydro-6h-pyrido 2,3-b 1,4 benzodiazepin-6-on
FI92068C (en) Process for the preparation of new therapeutically useful 7-fluoro-4-oxo-8- (1-piperazinyl) -1,4-dihydro-1,8-benzo [b] naphthyridine-3-carboxylic acids
JPH0441149B2 (en)
HU181000B (en) Process for preparing substituted 7,7-dimethyl-5h,7h-imidazo/4,5-h/-isoquinoline-4,6-diones
US4465683A (en) Anti-psychotic agents
US4260612A (en) Antiallergic nitrogen bridge-head compounds
JPS63500518A (en) Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
DE2361757A1 (en) Cardioactive imidazopyridines - substd. 2-phenyl 1H(or3H) imidazo (4,5,6) pyridines with positive inotropic and platelet aggregation inhibiting activity
US4061632A (en) 3,11-Dihydro-6H-pyrazolo[1,5-a]pyrazolo[4&#39;,3&#39;:5,6]-pyrido[4,3-d]pyrimidin-6-one derivatives
JPS6130588A (en) Benzo(c)(1,8)naphthylidine, manufacture, use and medicine
CS241026B2 (en) Method of pyrazolo(1,5-c)-quinozoline derivatives production
US4207322A (en) 6-Aryl-s-triazolo-(4,3-alpha)-pyrido-(2,3-f)-(1,4)-diazepines
JPS61129168A (en) 2-(4-substituted piperazin-4-oxyd-1-yl)-4-phenyl-quinoline derivative
IE43551B1 (en) Naphthyridine derivatives